Publications: Prof James Lindsay

Roukas C, Miller L, Büttner FC, Hamborg T, Stagg I, Hart A, Gordeev VS, Lindsay JO et al. ( 2024 ) . Impact of pain, fatigue and bowel incontinence on the quality of life of people living with inflammatory bowel disease: A UK cross‐sectional survey . United European Gastroenterology Journal

Blumenstein I, D’Haens G, Sands BE, Ferrante M, Matsuoka K, Lindsay JO, Mehra D, Charles L et al. ( 2024 ) . Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study . Zeitschrift für Gastroenterologie vol. 62 , ( 09 ) e608 - e609 .

Dubinsky MC, D’Haens G, Atreya R, Abraham B, Armuzzi A, Arguelles-Arias F, Lindsay JO, Patel K et al. ( 2024 ) . Risankizumab versus ustekinumab for the achievement of clinical outcomes and symptom improvement in patients with moderate to severe crohn’s disease: Results from the phase 3b SEQUENCE trial . Zeitschrift für Gastroenterologie vol. 62 , ( 09 ) e603 - e604 .

Pierre N, Huynh-Thu VA, Baiwir D, Mazzucchelli G, Fléron M, Trzpiot L, Eppe G, De Pauw E et al. ( 2024 ) . External validation of serum biomarkers predicting short-term and mid/long-term relapse in patients with Crohn’s disease stopping infliximab . Gut vol. 73 , ( 12 )

Peyrin-Biroulet L, Chapman JC, Colombel J-F, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R et al. ( 2024 ) . Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease . New England Journal of Medicine vol. 391 , ( 3 ) 213 - 223 .

Siegel CA, Rai V, Outtier A, Vermeire S, Law CCW, Sands BE, Abdulhamid A, Gearry R et al. ( 2024 ) . Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials . Journal of Crohn's and Colitisjjae097 - jjae097 .

Rodger B, Stagg AJ, Lindsay JO ( 2024 ) . The role of circulating T cells with a tissue resident phenotype (ex-TRM) in health and disease . Frontiers in Immunology vol. 15 ,

Tyler CJ, Hoti I, Griffiths DD, Cuff SM, Andrews R, Keisker M, Ahmed R, Hansen HP et al. ( 2024 ) . IL-21 conditions antigen-presenting human γδ T-cells to promote IL-10 expression in naïve and memory CD4+ T-cells . Discovery Immunology vol. 3 , ( 1 )

Humphreys DT, Lewis A, Pan‐Castillo B, Berti G, Mein C, Wozniak E, Gordon H, Gadhok R et al. ( 2024 ) . Single cell sequencing data identify distinct B cell and fibroblast populations in stricturing Crohn's disease . Journal of Cellular and Molecular Medicine vol. 28 , ( 9 )

Wyatt NJ, Watson H, Anderson CA, Kennedy NA, Raine T, Ahmad T, Allerton D, Bardgett M et al. ( 2024 ) . Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine . BMJ Open vol. 14 , ( 4 )

Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, Roberts C, Bishara M et al. ( 2024 ) . Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study . The Lancet Gastroenterology & Hepatology vol. 9 , ( 6 ) 521 - 538 .

Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, Lukin DJ et al. ( 2024 ) . Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure . Clinical Gastroenterology and Hepatology vol. 22 , ( 10 ) 2096 - 2106 .

Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ et al. ( 2024 ) . A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial . The Lancet Gastroenterology & Hepatology vol. 9 , ( 5 ) 415 - 427 .

Whelan K, Bancil AS, Lindsay JO, Chassaing B ( 2024 ) . Ultra-processed foods and food additives in gut health and disease . Nature Reviews Gastroenterology & Hepatology vol. 21 , ( 6 ) 406 - 427 .

Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B et al. ( 2024 ) . Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee . EClinicalMedicine vol. 69 ,

Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, Byrne J, Clarke C et al. ( 2024 ) . Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial . The Lancet Gastroenterology & Hepatology vol. 9 , ( 4 ) 333 - 345 .

Ferrante M, Panaccione R, Colombel JF, Dubinsky M, Hisamatsu T, Lindsay JO, Song A, Neimark E et al. ( 2024 ) . DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension . Journal of Crohn's and Colitis vol. 18 , ( Supplement_1 ) i168 - i170 .

Dubinsky MC, D’Haens G, Atreya R, Abraham B, Armuzzi A, Arguelles-Arias F, Lindsay JO, Patel K et al. ( 2024 ) . OP36 Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial . Journal of Crohn's and Colitis vol. 18 , ( Supplement_1 ) i65 - i66 .

D'Haens G, Sands BE, Ferrante M, Matsuoka K, Lindsay JO, Blumenstein I, Mehra D, Charles L et al. ( 2024 ) . P1009 Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study . Journal of Crohn's and Colitis vol. 18 , ( Supplement_1 ) i1823 - i1824 .

Gadhok R, Hornsby E, Kok KB, Lindsay JO, Stagg AJ ( 2024 ) . P120 A novel population of classical monocytes is expanded in CD and defined by an upregulation of genes relating to mononuclear cell differentiation and response to microbes . Journal of Crohn's and Colitis vol. 18 , ( Supplement_1 ) i410 - i410 .

Mathew L, Carlson S, Savage M, Pardieu C, Sze N, Munro C, Naglik J, Stagg A et al. ( 2024 ) . P145 Phagocyte responses to gut-derived C. albicans are modified in inflammatory bowel disease . Journal of Crohn's and Colitis vol. 18 , ( Supplement_1 ) i446 - i446 .

Blumenstein I, Torres J, Ma C, Lindsay JO, Ungaro R, Thin L, Lacerda AP, Anyanwu SI et al. ( 2024 ) . P509 Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn’s disease . Journal of Crohn's and Colitis vol. 18 , ( Supplement_1 ) i1007 - i1008 .

Long MD, Schreiber S, Hibi T, Gibble TH, Fisher DA, Park G, Moses RE, Higgins PDR et al. ( 2024 ) . Association of Bowel Urgency With Quality-of-Life Measures in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From Phase 3 LUCENT-1 (Induction) and LUCENT-2 (Maintenance) Studies . Crohn's & Colitis 360 vol. 6 , ( 1 )

Lindsay JO, Hind D, Swaby L, Berntsson H, Bradburn M, Bannur C U, Byrne J, Clarke C et al. ( 2024 ) . Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn's disease: the ASTIClite RCT . Efficacy and Mechanism Evaluation vol. 11 , ( 3 ) 1 - 106 .

Lewis A, Humphreys DT, Pan-Castillo B, Berti G, Felice C, Gordon H, Gadhok R, Nijhuis A et al. ( 2023 ) . Epigenetic and Metabolic Reprogramming of Fibroblasts in Crohn’s Disease Strictures Reveals Histone Deacetylases as Therapeutic Targets . Journal of Crohn's and Colitis vol. 18 , ( 6 ) 895 - 907 .

Peyrin-Biroulet L, Chapman C, Colombel J-F, Caprioli F, D’Haens G, Ferrante M, Schreiber S, Atreya R et al. ( 2023 ) . S1 Risankizumab Versus Ustekinumab in Patients With Moderate to Severe Crohn’s Disease: Results From the Phase 3B SEQUENCE Trial . The American Journal of Gastroenterology vol. 118 , ( 12S ) s1 - s1 .

Watanabe K, Peyrin-Biroulet L, Danese S, Fujitani Y, Faes M, Oortwijn A, Lindsay JO, Rogler G et al. ( 2023 ) . Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study . Journal of Crohn's and Colitis vol. 18 , ( 6 ) 801 - 811 .

Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, Levy G, Higgins PDR et al. ( 2023 ) . Efficacy and safety of upadacitinib for 16‐week extended induction and 52‐week maintenance therapy in patients with moderately to severely active ulcerative colitis . Alimentary Pharmacology & Therapeutics vol. 59 , ( 3 ) 393 - 408 .

Carlson SL, Mathew L, Savage M, Kok K, Lindsay JO, Munro CA, McCarthy NE ( 2023 ) . Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease . Journal of Fungi vol. 9 , ( 11 )

Gordon H, Wichmann K, Lewis A, Sanders T, Wildemann M, Hoti I, Hornsby E, Kok KB et al. ( 2023 ) . Human Intestinal Dendritic Cells Can Overcome Retinoic Acid Signaling to Generate Proinflammatory CD4 T Cells with Both Gut and Skin Homing Properties . The Journal of Immunology vol. 212 , ( 1 ) 96 - 106 .

Vieujean S, Lindsay JO, D'Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK, Nagahori M et al. ( 2023 ) . Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD . Journal of Crohn's and Colitis vol. 18 , ( 4 ) 548 - 559 .

Panaccione R, Panés J, Peyrin-Biroulet L, Colombel J-F, Lindsay J, Baert F, Atreya R, Lacerda AP et al. ( 2023 ) . S1193 Safety of Upadacitinib in IBD: Pooled Analysis of Phase 3 Maintenance Studies, U-ACHIEVE and U-ENDURE, In Patients With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease . The American Journal of Gastroenterology vol. 118 , ( 10S ) s909 - s910 .

Bai BYH, Reppell M, Smaoui N, Waring JF, Pivorunas V, Guay H, Lin S, Chanchlani N et al. ( 2023 ) . Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients . Journal of Crohn's and Colitis vol. 18 , ( 3 ) 431 - 445 .

Vermeire S, Danese S, Zhou W, Ilo D, Klaff J, Levy G, Yao X, Chen S et al. ( 2023 ) . Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study . The Lancet Gastroenterology & Hepatology vol. 8 , ( 11 ) 976 - 989 .

Mehandru S, Colombel J-F, Juarez J, Bugni J, Lindsay JO ( 2023 ) . Understanding the molecular mechanisms of anti-trafficking therapies and their clinical relevance in inflammatory bowel disease . Mucosal Immunology vol. 16 , ( 6 ) 859 - 870 .

Lim SH, Gros B, Sharma E, Lehmann A, Lindsay JO, Caulfield L, Gaya DR, Taylor J et al. ( 2023 ) . Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom . Inflammatory Bowel Diseases vol. 30 , ( 8 ) 1284 - 1294 .

Wong S-Y, Wellens J, Helmus D, Marlow L, Brann S, Pazos VM, Weinberg A, Moran HR et al. ( 2023 ) . Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium . Inflammatory Bowel Diseases vol. 29 , ( 11 ) 1693 - 1705 .

Ventham NT, Kennedy NA, Kalla R, Adams AT, Noble A, Ennis H, Group TS, Arnott I et al. ( 2023 ) . Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC) . Cellular and Molecular Gastroenterology and Hepatology vol. 16 , ( 3 ) 431 - 450 .

Lindsay JO, Picker N, Kromer D, Smyth M, Patel H ( 2023 ) . The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom . Current Medical Research and Opinion vol. 39 , ( 5 ) 681 - 689 .

Lu X, Zhou Z-Y, Xin Y, Wang M-J, Gray E, Jairath V, Lindsay JO ( 2024 ) . Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis . Inflammatory Bowel Diseases . vol. 30 , 64 - 77 .

Gordon H, Rodger B, Lindsay JO, Stagg AJ ( 2023 ) . Recruitment and Residence of Intestinal T Cells – Lessons for Therapy in Inflammatory Bowel Disease . Journal of Crohn's and Colitis vol. 17 , ( 8 ) 1326 - 1341 .

Alexander JL, Wyatt NJ, Camuzeaux S, Chekmeneva E, Jimenez B, Sands CJ, Fuller H, Takis P et al. ( 2023 ) . Considerations for peripheral blood transport and storage during large-scale multicentre metabolome research . Gut vol. 73 , ( 2 ) 379 - 383 .

Hornsby E, Gadhok R, Yadon AN, Lindsay JO, Stagg AJ ( 2023 ) . DOP04 Single cell RNA sequencing reveals a potential role for IFNγ in priming circulating monocytes for intestinal inflammatory function in Crohn’s Disease . Journal of Crohn's and Colitis vol. 17 , ( Supplement_1 ) i61 - i62 .

Roukas C, Miller L, Hamborg T, Gordeev V, Lindsay J, Norton C, Mihaylova B ( 2023 ) . DOP23 Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST survey . Journal of Crohn's and Colitis vol. 17 , ( Supplement_1 ) i87 - i88 .

Feagan BG, Horst S, Dryden G, Lindsay JO, Ferrante M, Dubenco E, Lacerda AP, Ford S et al. ( 2023 ) . OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies . Journal of Crohn's and Colitis vol. 17 , ( Supplement_1 ) i22 - i25 .

Vieujean S, Lindsay JO, Rubin D, D’Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK et al. ( 2023 ) . P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD . Journal of Crohn's and Colitis vol. 17 , ( Supplement_1 ) i794 - i797 .

Panés J, Loftus EV, Higgins PDR, Lindsay JO, Zhou W, Yao X, Ilo D, Phillips C et al. ( 2023 ) . Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results . Inflammatory Bowel Diseases vol. 29 , ( 9 ) 1421 - 1430 .

Louis E, Resche-Rigon M, Laharie D, Satsangi J, Ding N, Siegmund B, D'Haens G, Picon L et al. ( 2023 ) . Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial . The Lancet Gastroenterology & Hepatology vol. 8 , ( 3 ) 215 - 227 .

Vieujean S, Lindsay JO, Rubin D, D'Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK et al. ( 2023 ) . Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD . JOURNAL OF CROHNS & COLITIS . vol. 17 , 794 - 797 .

Roukas C, Miller L, Hamborg T, Gordeev V, Lindsay J, Norton C, Mihaylova B ( 2023 ) . Decrements in quality of life associated with symptoms of Inflammatory Bowel Disease: results from the UK IBD-BOOST survey . JOURNAL OF CROHNS & COLITIS . vol. 17 , I87 - I88 .

Hornsby E, Gadhok R, Yadon AN, Lindsay JO, Stagg AJ ( 2023 ) . Single cell RNA sequencing reveals a potential role for IFNγ in priming circulating monocytes for intestinal inflammatory function in Crohn's Disease . JOURNAL OF CROHNS & COLITIS . vol. 17 , I61 - I62 .

Feagan BG, Horst S, Dryden G, Lindsay JO, Ferrante M, Dubenco E, Lacerda AP, Ford S et al. ( 2023 ) . Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies . JOURNAL OF CROHNS & COLITIS . vol. 17 , I22 - I25 .

collaborators TEC ( 2022 ) . Development of a core descriptor set for Crohn's anal fistula . Colorectal Disease vol. 25 , ( 4 ) 695 - 706 .

Cox SR, Czuber-Dochan W, Wall CL, Clarke H, Drysdale C, Lomer MC, Lindsay JO, Whelan K ( 2022 ) . Improving Food-Related Quality of Life in Inflammatory Bowel Disease through a Novel Web Resource: A Feasibility Randomised Controlled Trial . Nutrients vol. 14 , ( 20 )

Lewis A, Sánchez S, Berti G, Pan-Castillo B, Nijhuis A, Mehta S, Eleid L, Gordon H et al. ( 2022 ) . Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease . Clinical Science vol. 136 , ( 19 ) 1405 - 1423 .

Saifuddin A, Kent AJ, Mehta SJ, Hicks LC, Gonzalez HA, Segal JP, Brookes MJ, Subramanian S et al. ( 2022 ) . Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID‐19 pandemic: the PREPARE‐IBD multicentre cohort study . Alimentary Pharmacology & Therapeutics vol. 56 , ( 10 ) 1460 - 1474 .

Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G et al. ( 2022 ) . Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials . The Lancet vol. 399 , ( 10341 ) 2113 - 2128 .

D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, Dubinsky M, Feagan BG et al. ( 2022 ) . Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials . The Lancet vol. 399 , ( 10340 ) 2015 - 2030 .

Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, Dubinsky M, Feagan BG et al. ( 2022 ) . Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial . The Lancet vol. 399 , ( 10340 ) 2031 - 2046 .

Ananthakrishnan AN, Kaplan GG, Bernstein CN, Burke KE, Lochhead PJ, Sasson AN, Agrawal M, Tiong JHT et al. ( 2022 ) . Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus . The Lancet Gastroenterology & Hepatology vol. 7 , ( 7 ) 666 - 678 .

Wellens J, Brann S, Adams A, Marlow L, Lindsay JO, Satsangi JJ ( 2022 ) . Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease . The Lancet Gastroenterology & Hepatology vol. 7 , ( 6 )

Hornsby E, King HW, Peiris M, Buccafusca R, Lee W-YJ, Wing ES, Blackshaw LA, Lindsay JO et al. ( 2022 ) . The cation channel TRPM8 influences the differentiation and function of human monocytes . Journal of Leukocyte Biology vol. 112 , ( 3 ) 365 - 381 .

Wellens J, Edmans M, Obolski U, Marlow L, Brann S, Dunachie S, Eyre D, Helmus D et al. ( 2022 ) . DOP20 Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium . Journal of Crohn's and Colitis vol. 16 , ( Supplement_1 ) i069 - i070 .

Mathew L, Savage M, Pardieu C, O’Brien M, Sze SK, Eberl M, Stagg A, Gasparetto M et al. ( 2022 ) . OP37 Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cells . Journal of Crohn's and Colitis vol. 16 , ( Supplement_1 ) i043 - i044 .

Rodger B, Gordon H, Hoti I, Stagg A, Lindsay J ( 2022 ) . P003 Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease . Journal of Crohn's and Colitis vol. 16 , ( Supplement_1 ) i136 - i136 .

Gordon H, Rodger B, Hornsby E, McGuire J, Kok KB, Lindsay JO, Stagg AJ ( 2022 ) . P039 The role of α4β7+CLA+ ‘dual tropic’ T cells in inflammatory bowel disease . Journal of Crohn's and Colitis vol. 16 , ( Supplement_1 ) i156 - i156 .

Lindsay J, Picker N, Kromer D, Smyth M, Patel H ( 2022 ) . P389 Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom . Journal of Crohn's and Colitis vol. 16 , ( Supplement_1 ) i387 - i388 .

Hosack T, Gadhok R, Lindsay JO ( 2022 ) . P584 Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease . Journal of Crohn's and Colitis vol. 16 , ( Supplement_1 ) i523 - i523 .

Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V et al. ( 2022 ) . Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases . The Lancet Gastroenterology & Hepatology vol. 7 , ( 3 ) 254 - 261 .

Raine T, Pavey H, Qian W, Moran GW, Subramanian S, Swaby L, Travis SP, Din S et al. ( 2022 ) . Establishment of a validated central reading system for ileocolonoscopy in an academic setting . Gut vol. 71 , ( 4 ) 661 - 664 .

Mathew L, Savage M, Pardieu C, O'Brien M, Sze SK, Eberl M, Stagg A, Gasparetto M et al. ( 2022 ) . Bacterial suppression of intestinal fungi via activation of human gut Vδ2+T-cells . JOURNAL OF CROHNS & COLITIS . vol. 16 , I043 - I044 .

Vermeire S, Danese S, Zhou W, Yao X, Ilo D, Liu J, Hebuterne X, Lindsay J et al. ( 2022 ) . Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Final Results From the Phase 3 U-ACHIEVE Maintenance Study . AMERICAN JOURNAL OF GASTROENTEROLOGY . vol. 117 , S521 - S522 .

Wellens J, Edmans M, Obolski U, Marlow L, Brann S, Dunachie S, Eyre D, Helmus D et al. ( 2022 ) . Functional viral neutralisation responses after SARS-CoV-2 infection in Inflammatory Bowel Disease patients receiving infusion therapies: Report from the ICARUS-IBD Consortium . JOURNAL OF CROHNS & COLITIS . vol. 16 , I069 - I070 .

Rodger B, Gordon H, Hoti I, Stagg A, Lindsay J ( 2022 ) . Identification of an intestine-derived ex-Trm population in the blood of healthy individuals and patients with Inflammatory Bowel Disease . JOURNAL OF CROHNS & COLITIS . vol. 16 , I136 - I136 .

Lindsay J, Picker N, Kromer D, Smyth M, Patel H ( 2022 ) . Indicators for inadequate response to advanced therapy in patients with Ulcerative Colitis: results from a medical chart review in the United Kingdom . JOURNAL OF CROHNS & COLITIS . vol. 16 , I387 - I388 .

Panes J, Loftus EVJ, Higgins P, Lindsay JO, Zhou W, Yao X, Ilo D, Phillips C et al. ( 2022 ) . Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance . JOURNAL OF CROHNS & COLITIS . vol. 16 , I373 - I374 .

Hosack T, Gadhok R, Lindsay JO ( 2022 ) . Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease . JOURNAL OF CROHNS & COLITIS . vol. 16 , I523 - I523 .

Gordon H, Rodger B, Hornsby E, McGuire J, Kok KB, Lindsay JO, Stagg AJ ( 2022 ) . The role of α4β7+CLA+ 'dual tropic' T cells in inflammatory bowel disease . JOURNAL OF CROHNS & COLITIS . vol. 16 , I156 - I156 .

Wong SY, Helmus D, Marlow L, Pazos VM, Brann S, Wellens J, Kedia S, Mak JWY et al. ( 2022 ) . Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium . JOURNAL OF CROHNS & COLITIS . vol. 16 , I357 - I358 .

Wellens J, Edmans M, Obolski U, McGregor CG, Simmonds P, Turner M, Jarvis L, Skelly D et al. ( 2021 ) . Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease . Gut vol. 71 , ( 9 ) 1919 - 1922 .

Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV et al. ( 2021 ) . Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial . The Lancet Gastroenterology & Hepatology vol. 7 , ( 2 ) 128 - 140 .

Danese S, Colombel J-F, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim H-S et al. ( 2021 ) . Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study . The Lancet Gastroenterology & Hepatology vol. 7 , ( 2 ) 118 - 127 .

Lindsay J, Din S, Hawkey C, Hind D, Irving P, Lobo A, Mahida Y, Moran G et al. ( 2021 ) . OFR-9 An RCT of autologous stem-cell transplantation in treatment refractory Crohn’s disease (low-intensity therapy evaluation): ASTIClite . Gut . Conference: Oral vol. 70 , a4 - a4 .

McCartney S, Lindsay JO, Russell RK, Gaya DR, Shaw I, Murray CD, Finney‐Hayward T, Sebastian S ( 2021 ) . Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease . Journal of Pediatric Gastroenterology and Nutrition vol. 74 , ( 2 ) 208 - 214 .

Alexander T, Snowden JA, Burman J, Chang H-D, Del Papa N, Farge D, Lindsay JO, Malard F et al. ( 2021 ) . Intestinal Microbiome in Hematopoietic Stem Cell Transplantation For Autoimmune Diseases: Considerations and Perspectives on Behalf of Autoimmune Diseases Working Party (ADWP) of the EBMT . Frontiers in Oncology vol. 11 ,

Wilson B, Eyice Ö, Koumoutsos I, Lomer MC, Irving PM, Lindsay JO, Whelan K ( 2021 ) . Prebiotic Galactooligosaccharide Supplementation in Adults with Ulcerative Colitis: Exploring the Impact on Peripheral Blood Gene Expression, Gut Microbiota, and Clinical Symptoms . Nutrients vol. 13 , ( 10 )

Schreiber S, Ferrante M, Panaccione R, Colombel J-F, Hisamatsu T, Lim A, Lindsay J, Rubin DT et al. ( 2021 ) . S695 Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies . The American Journal of Gastroenterology vol. 116 , ( 1 ) s314 - s315 .

Vermeire S, Danese S, Zhou W, Pangan A, Greenbloom S, D’Haens G, Panés J, Juillerat P et al. ( 2021 ) . S771 Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study . The American Journal of Gastroenterology vol. 116 , ( 1 ) s357 - s357 .

Feagan B, Lindsay J, Rogler G, Moran G, Varawalla N ( 2021 ) . S785 Alicaforsen Enema in Chronic Pouchitis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Trial . The American Journal of Gastroenterology vol. 116 , ( 1 ) s365 - s365 .

Cox SR, Clarke H, O’Keeffe M, Dubois P, Irving PM, Lindsay JO, Whelan K ( 2021 ) . Nutrient, Fibre, and FODMAP Intakes and Food-related Quality of Life in Patients with Inflammatory Bowel Disease, and Their Relationship with Gastrointestinal Symptoms of Differing Aetiologies . Journal of Crohn's and Colitis vol. 15 , ( 12 ) 2041 - 2053 .

Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Stagg AJ, Lindsay JO, Whelan K ( 2021 ) . Prebiotic fructans have greater impact on luminal microbiology and CD3+ T cells in healthy siblings than patients with Crohn's disease: A pilot study investigating the potential for primary prevention of inflammatory bowel disease . Clinical Nutrition vol. 40 , ( 8 ) 5009 - 5019 .

Lewis A, Pan-Castillo B, Berti G, Felice C, Gordon H, Gadhok R, Minicozzi A, Chinaleong J et al. ( 2021 ) . DOP23 Single-cell RNA sequencing identifies an important role for class I histone-deacetylase enzymes in intestinal myofibroblasts from patients with Crohn’s Disease strictures . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s062 - s062 .

Vermeire S, Danese S, Zhou W, Pangan A, Greenbloom S, D’Haens G, Panes J, Juillerat P et al. ( 2021 ) . OP23 Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s021 - s022 .

Schreiber SW, Ferrante M, Panaccione R, Colombel JF, Hisamatsu T, Lim A, Lindsay JO, Rubin DT et al. ( 2021 ) . OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s026 - s027 .

Rodger B, Hoti I, Gordon H, Lindsay J, Stagg A ( 2021 ) . P007 Identification and characterisation of intestine-derived circulating resident memory T cells (ex-Trm) in health and Inflammatory Bowel Disease . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s128 - s128 .

Gordon H, Rodger B, Hoti I, Lindsay JO, Stagg A ( 2021 ) . P033 Dendritic cells from patients with active IBD imprint pro-inflammatory α4β7+CLA+ T cells with potential for gut and skin homing . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s147 - s147 .

Hornsby E, Yadon AN, Clarke A, Grant E, Lindsay JO, Stagg AJ ( 2021 ) . P068 The combination of JAK1 and TPL2 or IRAK4 inhibitors is more effective than single agents in reducing TLR-mediated cytokine responses in human monocyte populations . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s173 - s173 .

Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A ( 2021 ) . P079 Valproic acid increases MiR449a expression in intestinal mucosa from patients with inflammatory bowel disease . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s181 - s181 .

Kabir M, Curtius K, Kalia P, Al Bakir I, Choi CHR, Hartono JL, East JE, Lindsay JO et al. ( 2021 ) . P109 Impact of ethnicity on colorectal cancer incidence in a cohort of colitis-associated dysplasia patients . Journal of Crohn's and Colitis vol. 15 , ( Supplement_1 ) s201 - s202 .

Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson M, East JE, Lindsay JO et al. ( 2021 ) . Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool . Gut

Dubinsky MC, Collins R, Abreu MT, Diseases IOFTSOIB, Abreu MT, Collins R, Dubinsky MC, Jairath V et al. ( 2021 ) . Challenges and Opportunities in IBD Clinical Trial Design . Gastroenterology vol. 161 , ( 2 ) 400 - 404 .

Wong S-Y, Dixon R, Pazos VM, Gnjatic S, Colombel J-F, Cadwell K, Group I-IW, Gold S et al. ( 2021 ) . Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies . Gastroenterology vol. 161 , ( 2 ) 715 - 718.e4 .

Whelan K, Murrells T, Morgan M, Cummings F, Stansfield C, Todd A, Sebastian S, Lobo A et al. ( 2021 ) . Food-related quality of life is impaired in inflammatory bowel disease and associated with reduced intake of key nutrients . American Journal of Clinical Nutrition vol. 113 , ( 4 ) 832 - 844 .

Panés J, Lindsay JO, Teich N, Lindgren S, Colombel J-F, Flynn HA, Huyck S, Yao R et al. ( 2021 ) . Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab . Inflammatory Bowel Diseases vol. 27 , ( 12 ) 1963 - 1967 .

McGregor CG, Adams A, Sadler R, Arancibia-Cárcamo CV, Palmer R, Ambrose T, Brain O, Walsh A et al. ( 2021 ) . Maintenance therapy with infliximab or vedolizumab in IBD is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic . Gut vol. 70 , ( 12 ) 2398 - 2400 .

Kim H, Alten R, Cummings F, Danese S, D’Haens G, Emery P, Ghosh S, de Saint Joseph CG et al. ( 2021 ) . Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters . mAbs vol. 13 , ( 1 )

Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP et al. ( 2021 ) . Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study . The Lancet Gastroenterology & Hepatology vol. 6 , ( 4 ) 271 - 281 .

Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J et al. ( 2021 ) . SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement . The Lancet Gastroenterology & Hepatology vol. 6 , ( 3 ) 218 - 224 .

Curtius K, Kabir M, Al Bakir I, Choi C-HR, Hartono J, Johnson M, East JE, Lindsay JO et al. ( 2021 ) . O17 Multi-centre validation of UC-CaRE: a cancer risk prediction tool for colitis-associated low grade dysplasia . Gut . Conference: Oral vol. 70 , a9 - a10 .

Gadhok R, Honap S, Ibarra A, Burgess N, Parkes G, Samaan M, Ray S, Mawdsley J et al. ( 2021 ) . P103 Ustekinumab: medium-term outcomes from a uk multi-centre real-world cohort . Gut . Conference: Posters vol. 70 , a94 - a95 .

Gordon H, Hoti I, Wichmann K, Saunders T, Wildemann M, Hornsby E, McCarthy NE, Lindsay JO et al. ( 2021 ) . P105 Dendritic cells imprint pro-inflammatory α4β7+CLA+ T cells with potential for gut and skin homing . Gut . Conference: Posters vol. 70 , a95 - a96 .

Kabir M, Curtius K, Al-Bakir I, Choi C-HR, Hartono J, Johnson M, East JE, Lindsay JO et al. ( 2021 ) . P115 Low grade dysplasia prognosis in the 21st century – a large multi-centre retrospective cohort study . Gut . Conference: Posters vol. 70 , a101 - a102 .

Feagan B, Lindsay J, Rogler G, Moran G, Varawalla N ( 2021 ) . Alicaforsen Enema in Chronic Pouchitis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Trial . AMERICAN JOURNAL OF GASTROENTEROLOGY . vol. 116 , S364 - S364 .

Vermeire S, Danese S, Zhou W, Pangan A, Greenbloom S, D'Haens G, Panes J, Juillerat P et al. ( 2021 ) . Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study . AMERICAN JOURNAL OF GASTROENTEROLOGY . vol. 116 , S357 - S357 .

Schreiber S, Ferrante M, Panaccione R, Colombel J-F, Hisamatsu T, Lim A, Lindsay J, Rubin DT et al. ( 2021 ) . Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies . AMERICAN JOURNAL OF GASTROENTEROLOGY . vol. 116 , S314 - S315 .

Lewis A, Pan-Castillo B, Berti G, Felice C, Gordon H, Gadhok R, Minicozzi A, Chinaleong J et al. ( 2021 ) . Single-cell RNA sequencing identifies an important role for class I histone-deacetylase enzymes in intestinal myofibroblasts from patients with Crohn's Disease strictures . JOURNAL OF CROHNS & COLITIS . vol. 15 , S062 - S062 .

Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A ( 2021 ) . Valproic acid increases MiR449a expression in intestinal mucosa from patients with inflammatory bowel disease . JOURNAL OF CROHNS & COLITIS . vol. 15 , S181 - S181 .

Bancil AS, Sandall AM, Rossi M, Chassaing B, Lindsay JO, Whelan K ( 2020 ) . Food Additive Emulsifiers and Their Impact on Gut Microbiome, Permeability, and Inflammation: Mechanistic Insights in Inflammatory Bowel Disease . Journal of Crohn's and Colitis vol. 15 , ( 6 ) 1068 - 1079 .

Felice C, Lewis A, Iqbal S, Gordon H, Rigoni A, Colombo MP, Armuzzi A, Feakins R et al. ( 2020 ) . Intestinal Inflammation is Linked to Hypoacetylation of Histone 3 Lysine 27 and can be Reversed by Valproic Acid Treatment in Inflammatory Bowel Disease Patients . Cellular and Molecular Gastroenterology and Hepatology vol. 11 , ( 3 )

Staudacher HM, Scholz M, Lomer MC, Ralph FS, Irving PM, Lindsay JO, Fava F, Tuohy K et al. ( 2020 ) . Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics . Clinical Nutrition vol. 40 , ( 4 ) 1861 - 1870 .

Dotan I, Panaccione R, Kaplan GG, O’Morain C, Lindsay JO, Abreu MT ( 2020 ) . Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force . Journal of Crohn's and Colitis vol. 14 , ( Supplement_3 ) s785 - s790 .

Sandall AM, Cox SR, Lindsay JO, Gewirtz AT, Chassaing B, Rossi M, Whelan K ( 2020 ) . Emulsifiers Impact Colonic Length in Mice and Emulsifier Restriction is Feasible in People with Crohn’s Disease . Nutrients vol. 12 , ( 9 )

Ball J, Clear A, Aries J, Charrot S, Besley C, Mee M, Stagg A, Lindsay J et al. ( 2020 ) . Retinoic acid-responsive CD8 effector T-cells are selectively increased in IL-23-rich tissue in gastrointestinal GvHD . Blood

Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA et al. ( 2020 ) . British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis . The Lancet Gastroenterology & Hepatology vol. 5 , ( 7 ) 679 - 697 .

Kennedy NA, Hansen R, Younge L, Mawdsley J, Beattie RM, Din S, Lamb CA, Smith PJ et al. ( 2020 ) . Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic . Frontline Gastroenterology vol. 11 , ( 5 )

Din S, Kent A, Pollok RC, Meade S, Kennedy NA, Arnott I, Beattie RM, Chua F et al. ( 2020 ) . Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel . Gut vol. 69 , ( 10 ) 1769 - 1777 .

Kennedy NA, Jones GR, Lamb CA, Appleby R, Arnott I, Beattie RM, Bloom S, Brooks AJ et al. ( 2020 ) . British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic . Gut

Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson MJ, East JE, Lindsay J et al. ( 2020 ) . Tu1814 MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR COLITIS PATIENTS WITH LOW GRADE DYSPLASIA USING UC-CARE: A PREDICTIVE CLINICAL DECISION SUPPORT TOOL . Gastroenterology vol. 158 , ( 6 )

Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B et al. ( 2020 ) . Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply . Alimentary Pharmacology & Therapeutics vol. 51 , ( 10 ) 997 - 998 .

Curtius K, Kabir M, Al Bakir I, Choi C-HR, Hartono J, Johnson M, East JE, Investigators OICS et al. ( 2020 ) . Multi-centre derivation and validation of a colitis-associated colorectal cancer risk prediction web-tool .

Rubin DT, Abreu MT, Rai V, Siegel CA, Disease IOFTSOIB, Ahuja V, Allez M, Ananthakrishnan AN et al. ( 2020 ) . Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting . Gastroenterology vol. 159 , ( 1 ) 6 - 13.e6 .

Levine A, Rhodes JM, Lindsay JO, Abreu MT, Kamm MA, Gibson PR, Gasche C, Silverberg MS et al. ( 2020 ) . Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases . Clinical Gastroenterology and Hepatology vol. 18 , ( 6 ) 1381 - 1392 .

Sandall A, Cox S, Lindsay JO, Rossi M, Whelan K ( 2020 ) . Food additive emulsifier restriction is feasible in people with Crohn's disease . Proceedings of The Nutrition Society vol. 79 , ( OCE1 )

Kabir M, Curtius K, Al-Bakir I, Hartono J, Johnson M, East JE, Lindsay JO, Vega R et al. ( 2020 ) . DOP41 Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study . Journal of Crohn's and Colitis vol. 14 , ( Supplement_1 ) s078 - s079 .

Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Zeroncio M et al. ( 2020 ) . DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study . Journal of Crohn's and Colitis vol. 14 , ( Supplement_1 ) s110 - s111 .

Gadhok R, Fragkos K, Honap S, Hassan J, Whiteley L, Ibarra A, Burgess N, Vega R et al. ( 2020 ) . P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort . Journal of Crohn's and Colitis vol. 14 , ( Supplement_1 ) s439 - s440 .

Staudacher H, Scholz M, Lomer M, Ralph F, Irving P, Lindsay J, Fava F, Tuohy K et al. ( 2020 ) . Diet and the microbiota in irritable bowel syndrome: Baseline associations and the impact of dietary intervention . NEUROGASTROENTEROLOGY AND MOTILITY . vol. 32 ,

Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Zeroncio M et al. ( 2020 ) . Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study . JOURNAL OF CROHNS & COLITIS . vol. 14 , S110 - S111 .

Gordon H, Murray J, Tailor F, Goh SA, Lindsay JO ( 2020 ) . Frequent disease relapse after withdrawal of infliximab in IBD patients with sustained remission . JOURNAL OF CROHNS & COLITIS . vol. 14 , S471 - S471 .

Kabir M, Curtius K, Al-Bakir I, Hartono J, Johnson M, East JE, Lindsay JO, Vega R et al. ( 2020 ) . Low-grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century: A large multi-centre retrospective cohort study . JOURNAL OF CROHNS & COLITIS . vol. 14 , S078 - S079 .

Curtius K, Kabir M, Al Bakir I, Choi CHR, Hartono JL, Johnson MJ, East JE, Lindsay J et al. ( 2020 ) . MULTI-CENTRE VALIDATION OF RISK STRATIFICATION FOR COLITIS PATIENTS WITH LOW GRADE DYSPLASIA USING UC-CARE: A PREDICTIVE CLINICAL DECISION SUPPORT TOOL . GASTROENTEROLOGY . vol. 158 , S1172 - S1173 .

Wilson B, Rossi M, Eyice O, Lomer MC, Irving PM, Lindsay JO, Whelan K ( 2020 ) . Prebiotic β-galacto-oligosaccharide impact on clinical, inflammatory and microbiota outcomes in active ulcerative colitis: An open-label study . Proceedings of the Nutrition Society . Conference: Nutrition Society

Gadhok R, Fragkos K, Honap S, Hassan J, Whiteley L, Ibarra A, Burgess N, Vega R et al. ( 2020 ) . Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort . JOURNAL OF CROHNS & COLITIS . vol. 14 , S439 - S440 .

Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B et al. ( 2019 ) . Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open . Alimentary Pharmacology & Therapeutics vol. 51 , ( 2 ) 271 - 280 .

Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Abbott JE, Michael E, Ahmad OF et al. ( 2019 ) . UK Patients of Bangladeshi Descent with Crohn’s Disease Respond Less Well to TNF Antagonists Than Caucasian Patients . Digestive Diseases and Sciences vol. 65 , ( 6 ) 1790 - 1799 .

Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N et al. ( 2019 ) . HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease . Gastroenterology vol. 158 , ( 1 ) 189 - 199 .

Cox SR, Lindsay JO, Fromentin S, Stagg AJ, McCarthy NE, Galleron N, Ibraim SB, Roume H et al. ( 2019 ) . Effects of Low-FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial . Gastroenterology

D'Haens GR, Lindsay JO, Loftus EV, Zhou W, Cataldi F, Xie W, Pugatch D, Panaccione R ( 2019 ) . 678 Efficacy of Upadacitinib as an Induction Therapy in Severe and Refractory Ulcerative Colitis: Sub-Group Analysis of the Phase 2b Study U-ACHIEVE . The American Journal of Gastroenterology . vol. 114 , s399 - s399 .

Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE et al. ( 2019 ) . British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults . Gut vol. 68 , ( Suppl 3 ) s1 - s106 .

Gadhok R, Rao R, Honap S, Samaan M, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al. ( 2019 ) . PTH-084 Ustekinumab: Early experience and medium-term outcomes from a UK multi-centre real-world cohort . Gut . Conference: Posters vol. 68 ,

Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E et al. ( 2019 ) . Autologous stem cell transplantation in refractory Crohn’s disease – low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study . BMC Gastroenterology vol. 19 , ( 1 )

Czuber‐Dochan W, Morgan M, Hughes LD, Lomer MCE, Lindsay JO, Whelan K ( 2019 ) . Perceptions and psychosocial impact of food, nutrition, eating and drinking in people with inflammatory bowel disease: a qualitative investigation of food‐related quality of life . Journal of Human Nutrition and Dietetics vol. 33 , ( 1 ) 115 - 127 .

Honap S, Gadhok R, Rao R, Samaan MA, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al. ( 2019 ) . Mo1917 – Ustekinumab: Early Experience and Medium-Term Outcomes from a Uk Multi-Centre Real-World Cohort . Gastroenterology vol. 156 , ( 6 )

D’Haens GRAM, Lindsay JO, Panaccione R, Schreiber S ( 2019 ) . Ulcerative Colitis: Shifting Sands . Drugs in R&D vol. 19 , ( 2 ) 227 - 234 .

Panés J, Lindsay JO, Teich N, Lindgren S, Colombel J-F, Cornillie F, Flynn HA, Huyck S et al. ( 2019 ) . Five-year Safety Data From OPUS, A European Observational Safety Registry For Adults With Ulcerative Colitis Treated With Originator Infliximab [Remicade®] Or Conventional Therapy . Journal of Crohn's and Colitis vol. 13 , ( 9 )

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R et al. ( 2019 ) . Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study . The Lancet Gastroenterology & Hepatology vol. 4 , ( 5 ) 341 - 353 .

Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, Anderson CA, Ananthakrishnan AN, Barrett JC et al. ( 2019 ) . Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease . JAMA vol. 321 , ( 8 ) 773 - 785 .

Lewis A, Nijhuis A, Berti G, Felice C, Jeffrey R, Iqbal S, Pomeranc AB, Aldelemi S et al. ( 2019 ) . DOP20 Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn’s disease . Journal of Crohn's and Colitis vol. 13 , ( Supplement_1 ) s037 - s038 .

Sandborn WJ, Schreiber S, Lee SD, Lindsay JO, Hebuterne X, Zhou W, Cataldi F, Lacerda AP et al. ( 2019 ) . OP14 Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with moderately to severely active ulcerative colitis: data from the U-ACHIEVE study . Journal of Crohn's and Colitis . vol. 13 , s009 - s009 .

Lewis A, Jeffrey R, Kumagai T, Hawkey CJ, Clark MM, Allez M, Satsangi J, Rogler G et al. ( 2019 ) . OP20 Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease . Journal of Crohn's and Colitis . vol. 13 , s014 - s014 .

Harrow P, Datta R, Stagg A, Lindsay JO ( 2019 ) . P012 IL22 expression in intestinal immune cells is not augmented by AHR activation in health or Crohn’s disease . Journal of Crohn's and Colitis . vol. 13 , s092 - s092 .

Hornsby E, Peiris M, Peiris M, King HW, Wing ES, Lindsay JO, Blackshaw LA, Stagg AJ ( 2019 ) . P016 Constitutive activity of the cation channel TRPM8 regulates monocyte to macrophage transition in humans to control intestinal inflammation . Journal of Crohn's and Colitis . vol. 13 , s094 - s094 .

Lewis A, Nijhuis A, Berti G, Bishop CL, Feakins R, Lindsay JO, Silver A ( 2019 ) . P035 Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn’s disease . Journal of Crohn's and Colitis . vol. 13 , s103 - s104 .

Hoti I, McCarthy N, Giles E, Ayada I, Harrow P, Gordon H, Stagg A, Lindsay J ( 2019 ) . P092 Circulating classical monocytes and intestinal macrophages exhibit reduced response to IL-10 in IBD . Journal of Crohn's and Colitis . vol. 13 , s131 - s132 .

Gadhok R, Rao R, Honap S, Samaan M, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al. ( 2019 ) . P318 Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort . Journal of Crohn's and Colitis . vol. 13 , s260 - s260 .

Rao R, Gadhok R, Whitley L, Burgess N, Amon P, Naik S, Lindsay J, McCartney S et al. ( 2019 ) . P616 Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres . Journal of Crohn's and Colitis . vol. 13 , s424 - s425 .

Kok K, Ibarra A, Lindsay J ( 2019 ) . New Therapeutic Strategies . Inflammatory Bowel Disease Nursing Manual , Springer Nature

Lewis A, Nijhuis A, Berti G, Felice C, Jeffrey R, Iqbal S, Pomeranc AB, Aldelemi S et al. ( 2019 ) . Drugs that modulate histone acetylation disrupt TGF-β-signalling and reduce collagen I expression in models of stricturing Crohn's disease . JOURNAL OF CROHNS & COLITIS . vol. 13 , S38 - S38 .

Honap S, Gadhok R, Rao R, Samaan MA, Harpham-Lockyer L, Kwok H, Whitley L, Ibarra A et al. ( 2019 ) . USTEKINUMAB: EARLY EXPERIENCE AND MEDIUM-TERM OUTCOMES FROM A UK MULTI-CENTRE REAL-WORLD COHORT . GASTROENTEROLOGY . vol. 156 , S885 - S886 .

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A et al. ( 2018 ) . Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies . Journal of Crohn's and Colitis vol. 13 , ( 1 ) 139 - 140 .

Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Biancheri P, Di Sabatino A, Feakins R, Silver A et al. ( 2018 ) . Epithelial down‐regulation of the miR‐200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition . Journal of Cellular and Molecular Medicine vol. 22 , ( 11 ) 5617 - 5628 .

Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, Muraro PA, Lindsay JO ( 2018 ) . Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases – a guide for the generalist . Clinical Medicine vol. 18 , ( 4 ) 329 - 334 .

Baker A-M, Cross W, Curtius K, Al Bakir I, Choi C-HR, Davis HL, Temko D, Biswas S et al. ( 2018 ) . Evolutionary history of human colitis-associated colorectal cancer . Gut vol. 68 , ( 6 )

Alexander T, Farge D, Badoglio M, Lindsay JO, Muraro PA, Snowden JA, Transplantation ADWPOTESFBAM ( 2018 ) . Hematopoietic stem cell therapy for autoimmune diseases – Clinical experience and mechanisms . Journal of Autoimmunity vol. 92 , 35 - 46 .

Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al. ( 2018 ) . ADWE-09 Low fodmap diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria in quiescent inflammatory bowel disease . Gut . Conference: Small Bowel & Nutrition vol. 67 ,

Czuber-Dochan W, Morgan M, Lomer M, Lindsay J, Robert G, Whelan K ( 2018 ) . OWE-037 Managing issues with food-related quality of life in inflammatory bowel disease – a qualitative study . Gut . Conference: Small Bowel & Nutrition vol. 67 ,

Cox SR, Stagg AJ, Fromentin S, Ehrlich SD, McCarthy NE, Galleron N, Levenez F, Lomer M et al. ( 2018 ) . 902 - Low Fodmap Diet Improves Functional-Like Gastrointestinal Symptoms but Reduces Bifidobacteria and Faecalibacterium Prausnitzii in Quiescent Inflammatory Bowel Disease: A Randomised Controlled Trial and Metagenomic Analysis . Gastroenterology vol. 154 , ( 6 ) s - 177 .

Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L et al. ( 2018 ) . Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis . Gastrointestinal Endoscopy vol. 88 , ( 2 ) 360 - 369.e2 .

Pockley AG, Lindsay JO, Foulds GA, Rutella S, Gribben JG, Alexander T, Snowden JA ( 2018 ) . Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Crohn's Disease: Current Status and Future Directions. A Review on Behalf of the EBMT Autoimmune Diseases Working Party and the Autologous Stem Cell Transplantation In Refractory CD-Low Intensity Therapy Evaluation Study Investigators . Front Immunol vol. 9 , 646 - 646 .

Irving PM, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al. ( 2018 ) . A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis . Inflammatory Bowel Diseases vol. 24 , ( 4 ) 714 - 724 .

Yarlas A, Rubin DT, Panés J, Lindsay JO, Vermeire S, Bayliss M, Cappelleri JC, Maher S et al. ( 2018 ) . Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36® Health Survey . Journal of Crohn's and Colitis vol. 12 , ( 5 ) 600 - 609 .

Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, Heap G et al. ( 2018 ) . DOP004 Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY . Journal of Crohn's and Colitis vol. 12 , ( suppl_1 ) s32 - s32 .

Harrow P, McCarthy N, Stagg A, Lindsay J ( 2018 ) . DOP017 Increased intestinal aryl hydrocarbon receptor expression and pathway sensitivity in Crohn’s disease . Journal of Crohn's and Colitis vol. 12 , ( supplement_1 ) s41 - s41 .

Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Tsilkos K et al. ( 2018 ) . DOP026 Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open . Journal of Crohn's and Colitis vol. 12 , ( supplement_1 ) s49 - s49 .

Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al. ( 2018 ) . DOP057 ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn’s disease: Summary of the ECCO-EBMT joint review . Journal of Crohn's and Colitis vol. 12 , ( supplement_1 ) s70 - s71 .

Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al. ( 2018 ) . DOP086 Low FODMAP diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria and faecalibacterium prausnitzii in Quiescent inflammatory bowel disease: a randomised controlled trial and metagenomic analysis . Journal of Crohn's and Colitis vol. 12 , ( supplement_1 ) s87 - s87 .

Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Feakins R, Silver A, Lindsay JO ( 2018 ) . P002 Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 family . Journal of Crohn's and Colitis vol. 12 , ( supplement_1 ) s91 - s92 .

Gordon H, Gadhok R, Ibarra A, Lindsay JO ( 2018 ) . P689 UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy . Journal of Crohn's and Colitis vol. 12 , ( supplement_1 ) s459 - s459 .

Snowden JA, Panés J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al. ( 2018 ) . Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn’s Disease: A Review on Behalf of ECCO and EBMT . Journal of Crohn's and Colitis vol. 12 , ( 4 ) 476 - 488 .

Snowden J, Panes J, Alexander T, Allez M, Ardizzone S, Dierickx D, Finke J, Hasselblatt P et al. ( 2018 ) . ECCO-EBMT joint paper: autologous haematopoietic stem cell transplantation (AHSCT) in severe Crohn's disease: Summary of the ECCO-EBMT joint review . JOURNAL OF CROHNS & COLITIS . vol. 12 , S70 - S71 .

Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Tsilkos K et al. ( 2018 ) . Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open . JOURNAL OF CROHNS & COLITIS . vol. 12 , S49 - S49 .

Mehta SJ, Lewis A, Nijhuis A, Jeffery R, Feakins R, Silver A, Lindsay JO ( 2018 ) . Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn's disease and is associated with down regulation of the miR-200 family . JOURNAL OF CROHNS & COLITIS . vol. 12 , S91 - S92 .

Lindsay JO, Woodland P ( 2018 ) . Gastrointestinal endoscopy . Edition ,

Cox SR, Stagg AJ, Fromentin S, Ehrlich SD, McCarthy NE, Galleron N, Levenez F, Lomer M et al. ( 2018 ) . LOW FODMAP DIET IMPROVES FUNCTIONAL-LIKE GASTROINTESTINAL SYMPTOMS BUT REDUCES BIFIDOBACTERIA AND FAECALIBACTERIUM PRAUSNITZII IN QUIESCENT INFLAMMATORY BOWEL DISEASE: A RANDOMISED CONTROLLED TRIAL AND METAGENOMIC ANALYSIS . GASTROENTEROLOGY . vol. 154 , S177 - S177 .

Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, Heap G et al. ( 2018 ) . Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY . JOURNAL OF CROHNS & COLITIS . vol. 12 , S32 - S32 .

Cox S, Stagg A, Fromentin S, Ehrlich D, McCarthy N, Galleron N, Levenez F, Lomer M et al. ( 2018 ) . Low FODMAP diet improves functional-like gastrointestinal symptoms but reduces bifidobacteria and faecalibacterium prausnitzii in Quiescent inflammatory bowel disease: a randomised controlled trial and metagenomic analysis . JOURNAL OF CROHNS & COLITIS . vol. 12 , S87 - S87 .

Czuber-Dochan W, Morgan M, Lomer M, Lindsay J, Robert G, Whelan K ( 2018 ) . MANAGING ISSUES WITH FOOD-RELATED QUALITY OF LIFE IN INFLAMMATORY BOWEL DISEASE - A QUALITATIVE STUDY . GUT . vol. 67 , A162 - A162 .

Gordon H, Gadhok R, Ibarra A, Lindsay JO ( 2018 ) . UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy . JOURNAL OF CROHNS & COLITIS . vol. 12 , S459 - S459 .

Rigoni A, Poulsom R, Jeffery R, Mehta S, Lewis A, Yau C, Giannoulatou E, Feakins R et al. ( 2017 ) . Separation of Dual Oxidase 2 and Lactoperoxidase Expression in Intestinal Crypts and Species Differences May Limit Hydrogen Peroxide Scavenging During Mucosal Healing in Mice and Humans . Inflamm Bowel Dis vol. 24 , ( 1 ) 136 - 148 .

Cox S, Prince A, Myers C, Irving PM, Lindsay JO, Lomer MC, Whelan K ( 2017 ) . Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial . Proceedings of The Nutrition Society . vol. 76 ,

Ball JA, Clear AJ, Calaminici M, Stagg A, Lindsay J, Gribben JG, Davies J ( 2017 ) . Human Gastro-Intestinal Graft-Versus-Host Disease Is Mediated By Retinoic Acid-Responsive CD8+ Effector T-Cells Under IL-23 Polarising Conditions . Blood . vol. 130 ,

Rossi M, Aggio R, Staudacher HM, Lomer MC, Lindsay JO, Irving P, Probert C, Whelan K ( 2017 ) . Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome . Clinical Gastroenterology and Hepatology vol. 16 , ( 3 ) 385 - 391.e1 .

Panés J, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H, Yarlas A et al. ( 2017 ) . Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies . Journal of Crohn's and Colitis vol. 12 , ( 2 ) 145 - 156 .

Cooper J, Blake I, Lindsay JO, Hawkey CJ ( 2017 ) . Living with Crohn’s disease: an exploratory cross-sectional qualitative study into decision-making and expectations in relation to autologous haematopoietic stem cell treatment (the DECIDES study) . BMJ Open vol. 7 , ( 9 )

Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H ( 2017 ) . Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease . Digestive and Liver Disease vol. 49 , ( 10 ) 1086 - 1091 .

Panés J, Rubin D, Vermeire S, Lindsay J, Sands B, Su C, Friedman G, Zhang H et al. ( 2017 ) . AODWE-004 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis . Gut . Conference: Inflammatory Bowel Disease vol. 66 ,

Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM et al. ( 2017 ) . A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial . Gastroenterology vol. 153 , ( 4 ) 936 - 947 .

Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K ( 2017 ) . Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial . Journal of Crohn's and Colitis vol. 11 , ( 12 ) 1420 - 1429 .

Lindsay JO, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al. ( 2017 ) . Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial . The Lancet Gastroenterology & Hepatology vol. 2 , ( 6 ) 399 - 406 .

Lindsay JO ( 2017 ) . Autologous Stem Cell Transplantation for Refractory Crohn’s Disease . Journal of Crohn's and Colitis vol. 11 , ( 10 ) 1157 - 1158 .

Gordon H, Gadhok R, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper BE, Lindsay JO ( 2017 ) . Sa1833 Anti-TNFS More Frequently Stopped Due to Loss of Response in British Asians with Crohn's Disease: A Single Centre Retrospective Analysis . Gastroenterology . vol. 152 ,

Gordon H, Hoti I, Lindsay JO, Stagg AJ ( 2017 ) . Tu1908 Circulating Non-Classical Monocytes are Reduced in Patients with Active IBD but Increase after Vedolizumab: A Role for α4β7 in Myeloid Cell Recruitment to the Inflamed Intestine . Gastroenterology . vol. 152 , s1003 - s1004 .

MCCARTHY NE, Tyler CJ, Lindsay JO, Stagg AJ, Moser B, Eberl M ( 2017 ) . Antigen-presenting human γδ T-cells promote intestinal CD4+ T-cell expression of IL-22 and mucosal release of calprotectin . Journal of Immunology

Lewis A, Felice C, Kumagai T, Lai C, Singh K, Jeffery RR, Feakins R, Giannoulatou E et al. ( 2017 ) . The miR-200 family is increased in dysplastic lesions in ulcerative colitis patients . PLoS One vol. 12 , ( 3 ) e0173664 - e0173664 .

Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, Gaya DR, Johnston BT et al. ( 2017 ) . UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care . Gut vol. 66 , ( 6 )

Nijhuis A, Curciarello R, Mehta S, Feakins R, Bishop CL, Lindsay JO, Silver A ( 2017 ) . MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8 . Cell Tissue Res

Hedin CR, van der Gast CJ, Stagg AJ, Lindsay JO, Whelan K ( 2017 ) . The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease . Gut Microbes vol. 8 , ( 4 ) 359 - 365 .

van Rheenen PF, Aloi M, Biron IA, Carlsen K, Cooney R, Cucchiara S, Cullen G, Escher JC et al. ( 2017 ) . European Crohn’s and Colitis Organisation Topical Review on Transitional Care in Inflammatory Bowel Disease . Journal of Crohn's and Colitis vol. 11 , ( 9 ) 1032 - 1038 .

Tranter M, Barakat F, Dogra H, Lindsay J, Croft N, Bulmer D ( 2017 ) . MMP-12, a novel mediator of nociception in Crohn's disease . JOURNAL OF CROHNS & COLITIS . Conference: European Crohn's and Colitis (ECCO) Congress 2017 vol. 11 , S120 - S120 .

Gisbert JP, Patel H, Nguyen G, Bokemeyer B, Armuzzi A, Lindsay J, Khalid J, Peyrin-Biroulet L ( 2017 ) . P-061 Impact of Dose Escalation with Anti-TNFs on Healthcare Resource Utilization Among Patients with Crohn's Disease: A Multi-Country Chart Review . Inflammatory Bowel Diseases vol. 23 , ( suppl_1 ) s25 - s25 .

Tranter M, Barakat F, Dogra H, Lindsay J, Croft N, Bulmer D ( 2017 ) . P086 MMP-12, a novel mediator of nociception in Crohn's disease . J Crohns Colitis . vol. 11 , S120 - S120 .

Hoti I, McCarthy NE, Giles EM, Ayada I, Gordon H, Stagg AJ, Lindsay JO ( 2017 ) . TNF alpha production by classical monocytes is poorly controlled by IL-10 in patients with IBD . JOURNAL OF CROHNS & COLITIS . Conference: 12th Congress of ECCO - European Crohn's and Colitis Organisation ( Barcelona, Spain ) from: 18/02/2017 to: 15/02/2017 , vol. 11 , S112 - S112 .

Lindsay JO, Irving PM, Mantzaris GJ, Panés J, Board OBOEECAEG ( 2017 ) . ECCO IBD Curriculum . Journal of Crohn's and Colitis vol. 11 , ( 9 ) 1039 - 1043 .

Le Bourhis L, Corraliza A, Auzolle C, Ricart E, Hawkey C, Lindsay JO, Clark M, Rogler G et al. ( 2017 ) . OP004 Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease . Journal of Crohn's and Colitis vol. 11 , ( suppl_1 ) s2 - s3 .

Gordon H, Hoti I, Lindsay JO, Stagg A ( 2017 ) . P053 Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for α4β7 in myeloid cell recruitment to the inflamed intestine . Journal of Crohn's and Colitis vol. 11 , ( suppl_1 ) s104 - s105 .

McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J ( 2017 ) . P059 Mucosal inflammation promotes activation of circulating Vδ2+ T-cells in Crohn's disease . Journal of Crohn's and Colitis . vol. 11 , s107 - s107 .

Panés J, Rubin DT, Vermeire S, Lindsay JO, Sands BE, Su C, Friedman G, Zhang H et al. ( 2017 ) . P467 Maintenance of quality of life improvement in a phase 3 study of tofacitinib for patients with moderately to severely active ulcerative colitis . Journal of Crohn's and Colitis vol. 11 , ( suppl_1 ) s315 - s317 .

Rubin DT, Panés J, Lindsay JO, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S et al. ( 2017 ) . P558 The SF-36® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis . Journal of Crohn's and Colitis vol. 11 , ( suppl_1 ) s364 - s365 .

Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO ( 2017 ) . P614 Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis . Journal of Crohn's and Colitis vol. 11 , ( suppl_1 ) s393 - s393 .

Brooks AJ, Smith PJ, Lindsay JO ( 2017 ) . Monitoring adolescents and young people with inflammatory bowel disease during transition to adult healthcare . Frontline Gastroenterology vol. 9 , ( 1 )

Yarlas A, Sands BE, Rubin DT, Lindsay J, Panes J, Vermeire S, Chen LA, Bayliss M et al. ( 2017 ) . A SYSTEMATIC REVIEW OF THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE FOR MEASURING HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS . VALUE IN HEALTH . vol. 20 , A185 - A185 .

Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO ( 2017 ) . ANTI-TNFS MORE FREQUENTLY STOPPED DUE TO LOSS OF RESPONSE IN BRITISH ASIANS WITH CROHN'S DISEASE: A SINGLE CENTRE RETROSPECTIVE ANALYSIS . GUT . vol. 66 , A255 - A255 .

Gadhok R, Gordon H, Sebepos-Rogers G, Baillie S, Akbar S, Ahmad OF, Cooper B, Lindsay JO ( 2017 ) . Anti-TNFs more frequently stopped due to loss of response in British Asians with Crohn's disease: a single centre retrospective analysis . JOURNAL OF CROHNS & COLITIS . vol. 11 , S393 - S393 .

Gordon H, Hoti I, Lindsay JO, Stagg A ( 2017 ) . Circulating non-classical monocytes are reduced in patients with active IBD but increase after vedolizumab: a role for α4β7 in myeloid cell recruitment to the inflamed intestine . JOURNAL OF CROHNS & COLITIS . vol. 11 , S104 - S105 .

Lewis A, Felice C, Nihjuis A, Iqbal S, Mehta S, Feakins R, Armuzzi A, Silver A et al. ( 2017 ) . Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's disease . JOURNAL OF CROHNS & COLITIS . vol. 11 , S17 - S17 .

Perez Gisbert J, Patel H, Nguyen G, Bokemeyer B, Armuzzi A, Lindsay J, Khalid J, Peyrin-Biroule L ( 2017 ) . Impact of Dose Escalation with Anti-TNFs on Healthcare Resource Utilization Among Patients with Crohn's Disease: A Multi-Country Chart Review . INFLAMMATORY BOWEL DISEASES . vol. 23 , S25 - S25 .

Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H ( 2017 ) . Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease . DIGESTIVE AND LIVER DISEASE vol. 49 , ( 10 ) 1086 - 1091 .

McCarthy N, Gordon H, Rahman S, Harrow P, Stagg A, Lindsay J ( 2017 ) . Mucosal inflammation promotes activation of circulating Vd2+T-cells in Crohn's disease . JOURNAL OF CROHNS & COLITIS . vol. 11 , S107 - S107 .

Le Bourhis L, Corraliza A, Auzolle C, Ricart E, Hawkey C, Lindsay JO, Clark M, Rogler G et al. ( 2017 ) . Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease . JOURNAL OF CROHNS & COLITIS . vol. 11 , S2 - S3 .

McCartney S, Lindsay J, Russell R, Gaya D, Shaw I, Murray C, Finney-Hayward T, Sebastian S ( 2017 ) . Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study . JOURNAL OF CROHNS & COLITIS . vol. 11 , S356 - S357 .

Rubin DT, Panes J, Lindsay JO, Vermeire S, Yarlas A, Bayliss M, Cappelleri JC, Maher S et al. ( 2017 ) . The SF-36r\® Health Survey distinguishes disease burden on functioning and well-being between patients with active vs inactive ulcerative colitis . JOURNAL OF CROHNS & COLITIS . vol. 11 , S364 - S365 .

McCartney S, Lindsay J, Russell R, Gaya D, Shaw I, Murray C, Finney-Hayward T, Sebastian S ( 2017 ) . The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study . JOURNAL OF CROHNS & COLITIS . vol. 11 , S261 - S262 .

Khalid JM, Peyrin-Biroulet L, Armuzzi A, Gisbert JP, Nguyen G, Bokemeyer B, Lindsay J, Smyth M et al. ( 2016 ) . Predictors of Non-response or Loss of Response to Tumour Necrosis Factor Antagonist Therapies in Inflammatory Bowel Disease . The American Journal of Gastroenterology . vol. 111 ,

Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ et al. ( 2016 ) . 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management . Journal of Crohn's and Colitis vol. 11 , ( 1 ) 3 - 25 .

Mowat C, Arnott I, Cahill A, Smith M, Ahmad T, Subramanian S, Travis S, Morris J et al. ( 2016 ) . Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial . The Lancet Gastroenterology & Hepatology vol. 1 , ( 4 ) 273 - 282 .

Lindsay J, Gisbert J, Mody R, Peyrin-Biroulet L, Armuzzi A, Bokemeyer B, Nguyen G, Siebenaler J et al. ( 2016 ) . PTH-070 A Multinational Study to Determine Indicators of Suboptimal Therapy Among Ulcerative Colitis Patients Treated with Tumour Necrosis Factor Antagonists . Gut . vol. 65 ,

Armuzzi A, Lindsay J, Mody R, Bokemeyer B, Gisbert J, Peyrin-Biroulet L, Nguyen G, Siebenaler J et al. ( 2016 ) . PTH-071 Indicators of Suboptimal Therapy Among Crohn’s Disease Patients Treated with Tumour Necrosis Factor Antagonists: Results from A Multi-National Study . Gut . vol. 65 ,

Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J ( 2016 ) . PTU-068 Dose Optimisation Using Drug and Antibody Levels Can Benefit 50% Patients Prescribed Anti TNF Therapy Compared to Empiric Dose Adjustment . Gut . vol. 65 ,

Peyrin‐Biroulet L, Germain A, Patel AS, Lindsay JO ( 2016 ) . Systematic review: outcomes and post‐operative complications following colectomy for ulcerative colitis . Alimentary Pharmacology & Therapeutics vol. 44 , ( 8 ) 807 - 816 .

Walton S-J, Lewis A, Jeffery R, Thompson H, Feakins R, Giannoulatou E, Yau C, Lindsay JO et al. ( 2016 ) . Familial adenomatous patients with desmoid tumours show increased expression of miR-34a in serum and high levels in tumours . Oncoscience vol. 3 , ( 5-6 ) 173 - 185 .

Hawkey CJ, Lindsay J, Gribben J ( 2016 ) . Stem Cell Transplantation for Refractory Crohn Disease—Reply . JAMA vol. 315 , ( 23 ) 2620 - 2621 .

Torres J, Caprioli F, Katsanos KH, Lobatón T, Micic D, Zerôncio M, Van Assche G, Lee JC et al. ( 2016 ) . Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases . Journal of Crohn's and Colitis vol. 10 , ( 12 ) 1385 - 1394 .

Giles EM, Sanders TJ, McCarthy NE, Lung J, Pathak M, MacDonald TT, Lindsay JO, Stagg AJ ( 2016 ) . Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease . Mucosal Immunology vol. 10 , ( 1 ) 184 - 193 .

Kennedy NA, Warner B, Johnston EL, Flanders L, Hendy P, Ding NS, Harris R, Fadra AS et al. ( 2016 ) . Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis . Alimentary Pharmacology & Therapeutics vol. 43 , ( 8 ) 910 - 923 .

Harrow P, Skinner C, Hoque T, Ibarra A, Lindsay J ( 2016 ) . Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti-TNF therapy compared with empiric dose adjustment . JOURNAL OF CROHNS & COLITIS . vol. 10 , S71 - S72 .

Cox S, Prince A, Myers C, Irving PM, Lindsay JO, Lomer MC, Whelan K ( 2016 ) . Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with quiescent inflammatory bowel disease: a double-blind, placebo-controlled, randomised, cross-over re-challenge trial . JOURNAL OF CROHNS & COLITIS . vol. 10 , S342 - S342 .

Tyler C, McCarthy N, Moser B, Stagg A, Eberl M, Lindsay J ( 2016 ) . Human intestinal Vδ2+T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: modulation by mucosal inflammation and vedolizumab therapy . JOURNAL OF CROHNS & COLITIS vol. 10 , S29 - S29 .

Lindsay J, Allez M, Clark M, Labopin M, Ricart E, Rogler G, Rovira M, Satsangi J et al. ( 2016 ) . Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn's disease: pooled results from the ASTIC trial . JOURNAL OF CROHNS & COLITIS . vol. 10 , S37 - S38 .

Arnott I, Mowat C, Ennis H, Keerie C, Lewis S, Kennedy N, Cahill A, Morris A et al. ( 2016 ) . The TOPPIC Trial: a randomised, double-blind parallel-group trial of mercaptopurine versus placebo to prevent recurrence of Crohn's disease following surgical resection in 240 patients . JOURNAL OF CROHNS & COLITIS . vol. 10 , S21 - S22 .

Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M et al. ( 2015 ) . Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial . JAMA vol. 314 , ( 23 ) 2524 - 2534 .

Hughes LD, King L, Morgan M, Ayis S, Direkze N, Lomer MC, Lindsay JO, Whelan K ( 2015 ) . Food-related Quality of Life in Inflammatory Bowel Disease: Development and Validation of a Questionnaire . Journal of Crohn's and Colitis vol. 10 , ( 2 ) 194 - 201 .

Anderson JL, Hedin CR, Benjamin JL, Koutsoumpas A, Ng SC, Hart AL, Forbes A, Stagg AJ et al. ( 2015 ) . Dietary intake of inulin-type fructans in active and inactive Crohn’s disease and healthy controls: a case–control study . Journal of Crohn's and Colitis vol. 9 , ( 11 ) 1024 - 1031 .

McCarthy NE, Hedin CR, Sanders TJ, Amon P, Hoti I, Ayada I, Baji V, Giles EM et al. ( 2015 ) . Azathioprine therapy selectively ablates human Vδ2+ T cells in Crohn’s disease . Journal of Clinical Investigation vol. 125 , ( 8 ) 3215 - 3225 .

Kennedy N, Lindsay J, Gordon J, Hart A, McCartney S, Irving P, Satsangi J, Lees C ( 2015 ) . OC-009 Withdrawal of anti-tnf following sustained remission for inflammatory bowel disease: a systematic review and meta-analysis . Gut . vol. 64 ,

Parisinos C, Ooi J, Lindsay J, Parkes G ( 2015 ) . OC-034 Probiotics for the prevention of antibiotic associated diarrhoea in the older inpatient population; a systematic review and meta-analysis . Gut . vol. 64 ,

Staudacher H, Lomer M, Lindsay J, Irving P, Whelan K ( 2015 ) . OC-103 The impact of low fodmap dietary advice and probiotics on symptoms in irritable bowel syndrome: a randomised, placebo-controlled, 2 × 2 factorial trial . Gut . vol. 64 ,

Irving P, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al. ( 2015 ) . PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis . Gut . vol. 64 ,

Tandiari T, Ibarra A, Younge L, Allepuz AP, Thompson A, Meade U, Arkir Z, Giles E et al. ( 2015 ) . PTH-083 Selective monitoring of antitnf drug levels and antibodies will reduce short-term prescribing costs and provide early personalised tailoring of antitnf therapy in routine ibd practice . Gut . vol. 64 ,

Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G, Satsangi J et al. ( 2015 ) . PTU-082 Responders to haemopoietic stem cell transplantation for crohn’s disease . Gut . vol. 64 ,

Sharratt C, Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G et al. ( 2015 ) . PTU-083 Substantial histological improvement following haemopoetic stem cell transplantation . Gut . vol. 64 ,

Mehta S, Nijhuis A, Kumagai T, Lindsay J, Silver A ( 2015 ) . Defects in the adherens junction complex (E-cadherin/ β-catenin) in inflammatory bowel disease . Cell Tissue Res vol. 360 , ( 3 ) 749 - 760 .

Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin-Biroulet L ( 2015 ) . Systematic review: The financial burden of surgical complications in patients with ulcerative colitis . Alimentary Pharmacology and Therapeutics vol. 41 , ( 11 ) 1066 - 1078 .

Lewis A, Mehta S, Hanna LN, Rogalski LA, Jeffery R, Nijhuis A, Kumagai T, Biancheri P et al. ( 2015 ) . Low Serum Levels of MicroRNA-19 Are Associated with a Stricturing Crohn's Disease Phenotype . Inflammatory Bowel Diseases vol. 21 , ( 8 ) 1926 - 1934 .

Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin‐Biroulet L ( 2015 ) . Systematic review: the financial burden of surgical complications in patients with ulcerative colitis . Alimentary Pharmacology & Therapeutics vol. 41 , ( 11 ) 1066 - 1078 .

Hedin C, van der Gast CJ, Rogers GB, Cuthbertson L, McCartney S, Stagg AJ, Lindsay JO, Whelan K ( 2015 ) . Siblings of patients with Crohn’s disease exhibit a biologically relevant dysbiosis in mucosal microbial metacommunities . Gut vol. 65 , ( 6 )

Biancheri P, Di Sabatino A, Curciarello R, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT ( 2015 ) . Mo1724 Interleukin-17A Homodimer Reduces Pro-Inflammatory Cytokine Production by Inflammatory Bowel Disease Mucosa Cultured Ex Vivo . Gastroenterology vol. 148 , ( 4 ) s - 695 .

van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F et al. ( 2015 ) . Segundo consenso europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática. Parte 3: situaciones especiales (versión española) . Revista de Gastroenterología de México vol. 80 , ( 1 ) 74 - 106 .

Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel J-F, Allez M, d’Haens G, d’Hoore A et al. ( 2015 ) . Segundo consenso europeo basado en evidencia sobre el diagnóstico y manejo de la colitis ulcerosa crónica idiopática. Parte 2: tratamiento actual (versión española) . Revista de Gastroenterología de México vol. 80 , ( 1 ) 32 - 73 .

Alexakis C, Nash A, Lloyd M, Brooks F, Lindsay JO, Poullis A ( 2015 ) . Inflammatory bowel disease in young patients: challenges faced by black and minority ethnic communities in the UK . Health & Social Care in the Community vol. 23 , ( 6 ) 665 - 672 .

Lewis A, Nijhuis A, Mehta S, Kumagai T, Feakins R, Lindsay JO, Silver A ( 2015 ) . Intestinal Fibrosis in Crohn's Disease: Role of microRNAs as Fibrogenic Modulators, Serum Biomarkers, and Therapeutic Targets . Inflammatory Bowel Diseases vol. 21 , ( 5 ) 1141 - 1150 .

Kennedy NA, Warner B, Johnston E, Flanders L, Hendy P, Ding N, Harris R, Fadra AS et al. ( 2015 ) . Anti-TNF withdrawal in IBD: Relapse and recapture rates and predictive factors from 160 patients in a pan-UK study . JOURNAL OF CROHNS & COLITIS vol. 9 , S41 - S42 .

Younge L, Lindsay J, Langmead L, Czuber-Dochan W ( 2015 ) . Assessing the satisfaction levels of older patients with different types of follow-up care for inflammatory bowel disease . JOURNAL OF CROHNS & COLITIS vol. 9 , S444 - S445 .

Irving P, Iqbal T, Nwokolo C, Subramanian S, Bloom S, Prasad N, Hart A, Murray C et al. ( 2015 ) . Cannabidiol for symptomatic treatment of ulcerative colitis: Results from a randomised, double-blind, placebo-controlled, parallel group, multi-centred pilot study . JOURNAL OF CROHNS & COLITIS vol. 9 , S287 - S287 .

Peyrin-Biroulet L, Patel AS, Lindsay JO ( 2015 ) . Colectomy is not a cure for ulcerative colitis: A systematic review . JOURNAL OF CROHNS & COLITIS vol. 9 , S280 - S281 .

Biancheri P, Di Sabatino A, Curciarello R, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT ( 2015 ) . Interleukin-17A Homodimer Reduces Pro-Inflammatory Cytokine Production by Inflammatory Bowel Disease Mucosa Cultured <i>Ex Vivo</i> . GASTROENTEROLOGY . vol. 148 , S695 - S695 .

Hawkey C, Allez M, Clark M, Labopin M, Lindsay J, Ricart E, Rogler G, Satsangi J et al. ( 2015 ) . Prolonged Deep Remission of Ileocolonic Crohn's Disease following Autologous Haemopoetic Stem Cell Transplantation, presented on behalf of all the ASTIC Trialists . JOURNAL OF CROHNS & COLITIS vol. 9 , S11 - S12 .

Felice C, Lewis A, Armuzzi A, Lindsay JO, Silver A ( 2015 ) . Review article: selective histone deacetylase isoforms as potential therapeutic targets in inflammatory bowel diseases . Aliment Pharmacol Ther vol. 41 , ( 1 ) 26 - 38 .

Lindsay JO, Peyrin-Biroulet L, Patel AS, Bergman A ( 2015 ) . Systematic review: The financial burden of surgical complications in patients with ulcerative colitis . JOURNAL OF CROHNS & COLITIS vol. 9 , S232 - S233 .

Parisinos CA, Harrow P, Langmead L, van Heel DA, Lindsay JO ( 2015 ) . eHealth optimises documentation and enables live access to IBD Multi Disciplinary Team outcomes . JOURNAL OF CROHNS & COLITIS vol. 9 , S366 - S367 .

Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W et al. ( 2014 ) . Segundo Consenso Europeo basado en evidencia sobre el diagnóstico y tratamiento de la colitis ulcerosa crónica idiopática Parte 1: Definiciones y diagnóstico (versión española) . Revista de Gastroenterología de México vol. 79 , ( 4 ) 263 - 289 .

Kennedy NA, Kalla R, Warner B, Gambles CJ, Musy R, Reynolds S, Dattani R, Nayee H et al. ( 2014 ) . Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients . Alimentary Pharmacology & Therapeutics vol. 40 , ( 11-12 ) 1313 - 1323 .

Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K et al. ( 2014 ) . HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants . Nat Genet vol. 46 , ( 10 ) 1131 - 1134 .

Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell JB, Vivian JP, So K et al. ( 2014 ) . HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants . Nature Genetics vol. 46 , ( 10 ) 1131 - 1134 .

( 2014 ) . Psychological Aspects of Inflammatory Bowel Disease, A biopsychosocial approach . Taylor & Francis

Nijhuis A, Biancheri P, Lewis A, Bishop CL, Giuffrida P, Chan C, Feakins R, Poulsom R et al. ( 2014 ) . In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts . Clin Sci (Lond) vol. 127 , ( 5 ) 341 - 350 .

Parkes GC, Whelan K, Lindsay JO ( 2014 ) . Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect . Journal of Crohn's and Colitis vol. 8 , ( 8 ) 717 - 725 .

Andreyev HJN, Muls AC, Norton C, Ralph C, Watson L, Shaw C, Lindsay JO ( 2014 ) . Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease . Frontline Gastroenterology vol. 6 , ( 1 )

Heap G, Singh A, Bewshea C, Weedon M, Cole A, Creed T, Greig E, Irving P et al. ( 2014 ) . OC-004 Thiopurine Induced Pancreatitis In Inflammatory Bowel Disease: Clinical Features And Genetic Determinants . Gut vol. 63 Suppl 1 , A2 - A3 .

Hedin C, van der Gast C, Rogers G, McCartney S, Stagg A, Lindsay J, Whelan K ( 2014 ) . OC-051 Siblings Of Crohn's Disease Patients Exhibit A Biologically Relevant Dysbiosis In The Mucosal Microbial Community: A 16s Rrna Gene Pyrosequencing Study . Gut vol. 63 Suppl 1 ,

Hughes L, Lindsay J, Lomer M, Ayis S, King L, Morgan M, Whelan K ( 2014 ) . PTU-102 Development Of A Food Related Quality Of Life Questionnaire For People With Ibd . Gut vol. 63 Suppl 1 ,

Russo E, Hackett R, Campbell S, Lindsay J, Irving P, Orchard T ( 2014 ) . PWE-071 Efficacy Of Infliximab As Second-line Biologic In Crohn's Disease . Gut vol. 63 Suppl 1 , A154 - A155 .

Biancheri P, Di Sabatino A, Curciarello R, Corazza G, Lindsay J, MacDonald T ( 2014 ) . PWE-087 Interleukin-17a Homodimer Reduces Pro-inflammatory Cytokine Production By Inflammatory Bowel Disease Mucosa Cultured Ex Vivo . Gut vol. 63 Suppl 1 ,

Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA et al. ( 2014 ) . 6 Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants . Gastroenterology vol. 146 , ( 5 ) s - 2 .

Sanders TJ, McCarthy NE, Giles EM, Davidson KLM, Haltalli MLR, Hazell S, Lindsay JO, Stagg AJ ( 2014 ) . Increased production of retinoic acid by intestinal macrophages contributes to their inflammatory phenotype in patients with Crohn's disease . Gastroenterology vol. 146 , ( 5 )

Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, Thomas M, Lindsay JO, Stagg AJ ( 2014 ) . Sa1778 Constitutive Type I Interferon, via STAT1 Activation, Selectively Promotes Regulatory T Cell Function in the Healthy Human Intestine, but Not in Inflammatory Bowel Disease . Gastroenterology . vol. 146 ,

MacFie TS, Poulsom R, Parker A, Warnes G, Boitsova T, Nijhuis A, Suraweera N, Poehlmann A et al. ( 2014 ) . DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid . Inflamm Bowel Dis vol. 20 , ( 3 ) 514 - 524 .

Hedin C, van der Gast C, Rogers G, McCartney S, Stagg AJ, Lindsay JO, Whelan K ( 2014 ) . OP020 16S rRNA gene pyrosequencing indicate that siblings of Crohn's disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities . Journal of Crohn's and Colitis vol. 8 , ( Supplement_1 ) s11 - s12 .

Biancheri P, Di Sabatino A, Curciarello R, Giuffrida P, Ammoscato F, Corazza GR, Lindsay JO, MacDonald TT ( 2014 ) . P053 Interleukin-17A homodimer reduces pro-inflammatory cytokine production by inflammatory bowel disease mucosa cultured ex vivo . Journal of Crohn's and Colitis vol. 8 , ( Supplement_1 ) s85 - s85 .

Hedin CR, McCarthy NE, Louis P, Farquharson FM, McCartney S, Taylor K, Prescott NJ, Murrells T et al. ( 2014 ) . Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings . Gut

McCarthy NE, Hedin CR, Sanders TJ, Amon P, Baji V, Giles EM, Wildemann M, Bashir Z et al. ( 2014 ) . Colonic Vδ2+T-cells display elevated TNF production and reversible ablation by azathioprine therapy in Crohn's disease . IMMUNOLOGY . vol. 143 , 165 - 165 .

Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, Thomas M, Lindsay JO, Stagg AJ ( 2014 ) . Constitutive Type I Interferon, via STAT1 Activation, Selectively Promotes Regulatory T Cell Function in the Healthy Human Intestine, but Not in Inflammatory Bowel Disease . GASTROENTEROLOGY . vol. 146 , S293 - S294 .

Giles E, Sanders TJ, McCarthy NE, Sanderson I, Lindsay J, MacDonald TT, Stagg AJ ( 2014 ) . Constitutive Type I Interferon, via STAT1 activation, selectively promotes regulatory T cell function in the healthy human intestine, but not in IBD . IMMUNOLOGY . vol. 143 , 17 - 17 .

Parkes GC, Whelan K, Lindsay JO ( 2014 ) . Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect . Journal of Crohn's and Colitis

Heap GA, Singh A, Bewshea CM, Weedon M, Dubois P, Andrews JM, Annese V, Bampton PA et al. ( 2014 ) . Thiopurine Induced Pancreatitis in Inflammatory Bowel Disease: Clinical Features and Genetic Determinants . GASTROENTEROLOGY . vol. 146 , S2 - S2 .

Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO ( 2013 ) . Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial . Lancet vol. 382 , ( 9910 ) 2084 - 2092 .

Goodhand JR, Kamperidis N, Sirwan B, Macken L, Tshuma N, Koodun Y, Chowdhury FA, Croft NM et al. ( 2013 ) . Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease . Aliment Pharmacol Ther vol. 38 , ( 9 ) 1097 - 1108 .

Allison M, Lindsay J, Gould D, Kelly D ( 2013 ) . Surgery in young adults with inflammatory bowel disease: a narrative account . Int J Nurs Stud vol. 50 , ( 11 ) 1566 - 1575 .

McCarthy NE, Bashir Z, Vossenkämper A, Hedin CR, Giles EM, Bhattacharjee S, Brown SG, Sanders TJ et al. ( 2013 ) . Proinflammatory Vδ2+ T cells populate the human intestinal mucosa and enhance IFN-γ production by colonic αβ T cells . J Immunol vol. 191 , ( 5 ) 2752 - 2763 .

Lindsay JO, Chipperfield R, Giles A, Wheeler C, Orchard T, INDIGO study investigators ( 2013 ) . A UK retrospective observational study of clinical outcomes and healthcare resource utilisation of infliximab treatment in Crohn's disease . Aliment Pharmacol Ther vol. 38 , ( 1 ) 52 - 61 .

Mehta SJ, Silver AR, Lindsay JO ( 2013 ) . Review article: strategies for the management of chronic unremitting ulcerative colitis . Aliment Pharmacol Ther vol. 38 , ( 2 ) 77 - 97 .

Hawkey C, Allez M, Ardizzone S, Clark L, Columbel J-F, Danese S, Farge-Bancel D, Labopin M et al. ( 2013 ) . OC-014 Clinical and Endoscopic Improvement following Hemopoietic Stem Cell Transplantation vs Mobilisatiion alone in Crohn’S Disease . Gut vol. 62 , ( Suppl 1 )

Hedin C, McCarthy NE, Louis P, Farquharson F, McCartney S, Taylor K, Prescott N, Murrells T et al. ( 2013 ) . OC-017 A Discriminant Analysis Demonstrates that Siblings of Patients with Crohn’S Disease have a Distinct Microbiological and Immune Phenotype Compared with Healthy Controls: Insights into Disease Pathogenesis . Gut vol. 62 , ( Suppl 1 )

Hedin C, McCarthy NE, Louis P, Farquharson F, McCartney S, Taylor K, Prescott NJ, Murrells T et al. ( 2013 ) . 260 Siblings of Patients With Crohn's Disease Have a Distinct Microbiological and Immune Phenotype Compared to Healthy Controls: Insights Into Disease Pathogenesis . Gastroenterology vol. 144 , ( 5 )

Landy J, Wahed M, Peake STC, Hussein M, Ng SC, Lindsay JO, Hart AL ( 2013 ) . Oral tacrolimus as maintenance therapy for refractory ulcerative colitis-an analysis of outcomes in two London tertiary centres . Journal of Crohn's and Colitis vol. 7 , ( 11 )

Biancheri P, Di Sabatino A, Nijhuis A, Lai C, Ghosh A, Macdonald TT, Lindsay J, Silver A et al. ( 2013 ) . OC.07.1 MICRO-RNA EXPRESSION PROFILING IDENTIFIES MIR-29B AS A RELEVANT PRO-FIBROGENIC FACTOR IN CROHN'S DISEASE INTESTINAL STRICTURES . Digestive and Liver Disease vol. 45 , s70 - s71 .

Biancheri P, Nijhuis A, Di Sabatino A, Lai C, Ghosh A, MacDonald TT, Corazza GR, Lindsay J et al. ( 2013 ) . P057 Micro-RNA expression profiling identifies miR-29b as a relevant pro-fibrogenic factor in Crohn's disease intestinal strictures . Journal of Crohn's and Colitis vol. 7 , ( Supplement_1 ) s32 - s32 .

McCarthy N, Hedin C, Bashir Z, Vossenkämper A, Giles E, Sanders T, Whelan K, MacDonald T et al. ( 2013 ) . P066 Human intestinal Vδ2+ T-cells promote mucosal inflammation in Crohn's disease and are selectively ablated by azathioprine therapy . Journal of Crohn's and Colitis vol. 7 , ( Supplement_1 ) s35 - s36 .

Goodhand J, Kamperidis N, Sirwan B, Macken L, Tshuma N, Koodun Y, Chowdhury F, Croft N et al. ( 2013 ) . P335 Thiopurine nonadherence is more common in adolescents than adults with IBD, is associated with psychological distress and impacts on the management and prognosis . Journal of Crohn's and Colitis . vol. 7 , s144 - s144 .

Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F et al. ( 2013 ) . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations . Journal of Crohn's and Colitis vol. 7 , ( 1 ) 1 - 33 .

Andreyev HJ, Benton B, Lalji A, Pennert K, Lindsay JO, Gage H, Norton C ( 2013 ) . ALGORITHMIC MANAGEMENT OF RADIATION-INDUCED GI SYMPTOMS IS HIGHLY EFFECTIVE: THE ORBIT RANDOMISED CONTROLLED TRIAL . GUT . vol. 62 , A29 - A30 .

Andreyev HJN, Benton BE, Lalji A, Norton C, Mohammed K, Gage H, Pennert K, Lindsay JO ( 2013 ) . Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): A randomised controlled trial . The Lancet vol. 382 , ( 9910 ) 2084 - 2092 .

Hawkey C, Allez M, Ardizzone S, Clark E, Clark M, Colombel JF, Danese S, Farge-Bancel D et al. ( 2013 ) . Clinical and endoscopic improvement following haemopoietic stem cell transplantation on behalf of the Autoimmune Diseases Working Party of the EBMT . BONE MARROW TRANSPLANTATION . vol. 48 , S44 - S44 .

Giles E, Pathak M, Sanders TJ, McCarthy NE, Sanderson IR, MacDonald TT, Lindsay JO, Stagg AJ ( 2013 ) . Constitutive Type I Interferon, via STAT1 activation, promotes regulatory T cell function in the healthy human intestine, but not in inflammatory bowel disease . IMMUNOLOGY . vol. 140 , 168 - 168 .

Sanders TJ, McCarthy NE, Giles EM, Davidson KLM, Haltalli MLR, Hazell S, Lindsay JO, Stagg AJ ( 2013 ) . Retinoic acid generation by human intestinal CD14<SUP>+</SUP> macrophages is enhanced in Crohn's disease and maintains an inflammatory phenotype . IMMUNOLOGY . vol. 140 , 32 - 32 .

Hedin C, McCarthy NE, Louis P, Farquharson F, McCartney S, Taylor K, Prescott NJ, Murrells T et al. ( 2013 ) . Siblings of Patients With Crohn's Disease Have a Distinct Microbiological and Immune Phenotype Compared to Healthy Controls: Insights Into Disease Pathogenesis . GASTROENTEROLOGY . vol. 144 , S57 - S58 .

Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel J-F, Allez M, D'Haens G, D'Hoore A et al. ( 2012 ) . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management . Journal of Crohn's and Colitis vol. 6 , ( 10 ) 991 - 1030 .

Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, Mantzaris G, Reinisch W et al. ( 2012 ) . Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis . Journal of Crohn's and Colitis vol. 6 , ( 10 ) 965 - 990 .

Kamperidis N, Goodhand JR, Chowdhury FA, Koodun Y, Direzke NC, Naik S, Sanderson IR, Croft NM et al. ( 2012 ) . Factors associated with nonadherence to thiopurines in adolescent and adult patients with inflammatory bowel disease . J Pediatr Gastroenterol Nutr vol. 54 , ( 5 ) 685 - 689 .

Biancheri P, Nijhuis A, Lai C, Ghosh A, Feakins R, Chan C, Di Sabatino A, Corazza GR et al. ( 2012 ) . Tu1915 Differential MicroRNA Expression Profiles in Crohn's Disease Strictured Versus Non-Strictured Intestine . Gastroenterology vol. 142 , ( 5 ) s - 877 .

Goodhand JR, Kamperidis N, Joshi NM, Wahed M, Koodun Y, Cantor EJ, Croft NM, Langmead FL et al. ( 2012 ) . The phenotype and course of inflammatory bowel disease in UK patients of Bangladeshi descent . Aliment Pharmacol Ther vol. 35 , ( 8 ) 929 - 940 .

Goodhand JR, Kamperidis N, Rao A, Laskaratos F, McDermott A, Wahed M, Naik S, Croft NM et al. ( 2012 ) . Prevalence and management of anemia in children, adolescents, and adults with inflammatory bowel disease . Inflamm Bowel Dis vol. 18 , ( 3 ) 513 - 519 .

Hedin CR, Stagg AJ, Whelan K, Lindsay JO ( 2012 ) . Family studies in Crohn's disease: new horizons in understanding disease pathogenesis, risk and prevention . Gut vol. 61 , ( 2 ) 311 - 318 .

Macfie T, Parker A, Nijhuis A, Boitsova T, Suraweera N, Jeffery R, Poulsom R, Lindsay J et al. ( 2012 ) . 5-ASA ENHANCES <i>DUOX2</i> EXPRESSION IN ACTIVE ULCERATIVE COLITIS: A RISK FOR COLORECTAL CANCER? . GUT vol. 61 , A401 - A402 .

Tshuma N, Aboulela S, Chowdhury F, Macken L, Kamperidis N, Goodhand J, Lindsay J ( 2012 ) . BSG information group symposium & free papers: "Social media and apps: new opportunities, new risks" CONTENT ANALYSIS OF ILLNESS BLOGS POSTED ONLINE BY PATIENTS WITH IBD . GUT vol. 61 , A68 - A69 .

Biancheri P, Nijhuis A, Lai C, Ghosh A, Feakins R, Chan C, Di Sabatino A, Corazza GR et al. ( 2012 ) . Differential MicroRNA Expression Profiles in Crohn's Disease Strictured Versus Non-Strictured Intestine . GASTROENTEROLOGY . vol. 142 , S877 - S877 .

McCarthy NE, Hedin CR, Vossenkaemper A, Bhattacharjee S, Brown SG, Sanders TJ, Giles EM, Whelan K et al. ( 2012 ) . HUMAN ANTI-MICROBIAL Vδ2+T-CELLS ARE NOVEL INTESTINAL LYMPHOCYTES WITH FUNCTIONAL RELEVANCE IN CROHN'S DISEASE . GUT . vol. 61 , A4 - A4 .

Sanders TJ, McCarthy NE, Giles E, Lindsay JO, Stagg AJ ( 2012 ) . INTESTINAL INFLAMMATION REGULATES RETINOIC ACID DEPENDENT IMPRINTING OF GUT TROPISM BY DENDRITIC CELLS INDEPENDENTLY OF RALDH EXPRESSION . GUT . vol. 61 , A402 - A402 .

Hedin CR, Taylor K, Louis P, Farquharson F, McCartney S, Prescott NJ, Stagg AJ, Lindsay JO et al. ( 2012 ) . MICROBIAL, PHENOTYPIC AND GENETIC MARKERS OF RISK: ASPECTS OF CROHN'S DISEASE THAT ARE SHARED BY UNAFFECTED SIBLINGS . GUT vol. 61 , A22 - A23 .

Nijhuis A, Biancheri P, Lai C, Ghosh A, Boitsova T, Chan C, MacDonald T, Lindsay J et al. ( 2012 ) . MICRORNA EXPRESSION PROFILING IN STRICTURING CROHN'S DISEASE IDENTIFIES MIR-34A AS A FUNCTIONALLY RELEVANT INFLUENCE ON DISEASE PHENOTYPE . GUT vol. 61 , A167 - A168 .

Andreyev HJ, Thomas K, Benton B, Lalji A, Lindsay JO, Gage H, Norton C ( 2012 ) . OPTIMISING RADIATION BOWEL INJURY THERAPY, THE ORBIT STUDY, A RANDOMISED CONTROLLED TRIAL . GUT vol. 61 , A36 - A36 .

Hedin CR, Louis P, Farquharson F, McCartney S, Stagg AJ, Lindsay JO, Whelan K ( 2012 ) . PREBOTICS AS PRIMARY PREVENTION OF CROHN'S DISEASE: IMPACT ON LUMINAL MICROBIOLOGY AND ELEVATED FAECAL CALPROTECTIN IS GREATER IN HEALTHY SIBLINGS THAN IN PATIENTS . GUT vol. 61 , A171 - A171 .

Houston Y, Lindsay JO, Jenkins H, McCartney S, Ahmad T, Arnott I, Croft N, Russell R et al. ( 2012 ) . Perspectives of transition care in inflammatory bowel disease: A survey . Gastrointestinal Nursing vol. 10 , ( 1 ) 30 - 35 .

Sanders TJ, McCarthy NE, Giles EM, Lindsay JO, Stagg AJ ( 2012 ) . Retinoic acid production in the human intestine: antigen presenting cell retinaldehyde dehydrogenase activity is enhanced in inflammatory bowel disease . IMMUNOLOGY . vol. 137 , 78 - 78 .

Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Prescott NJ, Pessoa-Lopes P, Mathew CG et al. ( 2012 ) . Smokers with active Crohn's disease have a clinically relevant dysbiosis of the gastrointestinal microbiota . INFLAMMATORY BOWEL DISEASES vol. 18 , ( 6 ) 1092 - 1100 .

Sanders TJ, McCarthy NE, Giles EM, Lindsay JO, Stagg AJ ( 2012 ) . THE ROLE OF RDH10 AND RALDH ENZYMES IN RETINOIC ACID-MEDIATED IMMUNE REGULATION BY ANTIGEN PRESENTING CELLS IN THE HUMAN INTESTINE . GUT . vol. 61 , A402 - A403 .

Sebastian S, Jenkins H, McCartney S, Ahmad T, Arnott I, Croft N, Russell R, Lindsay JO ( 2012 ) . The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and paediatric gastroenterologists . JOURNAL OF CROHNS & COLITIS vol. 6 , ( 8 ) 830 - 844 .

Goodhand J, Hedin CR, Croft NM, Lindsay JO ( 2011 ) . Adolescents with IBD: the importance of structured transition care . J Crohns Colitis vol. 5 , ( 6 ) 509 - 519 .

Benton B, Norton C, Lindsay J, Dolan S, Andreyev HJN ( 2011 ) . Can Nurses Manage Gastrointestinal Symptoms Arising from Pelvic Radiation Disease? . CLIN ONCOL-UK vol. 23 , ( 8 ) 538 - 551 .

Ng SC, Benjamin JL, McCarthy NE, Hedin CRH, Koutsoumpas A, Plamondon S, Price CL, Hart AL et al. ( 2011 ) . Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease . Inflamm Bowel Dis vol. 17 , ( 10 ) 2027 - 2037 .

Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, Kamm MA, Sanderson JD et al. ( 2011 ) . Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease . Gut vol. 60 , ( 7 ) 923 - 929 .

Hedin CR, McCarthy NE, Bhattacharjee S, James G, Whelan K, Lindsay JO, Stagg AJ ( 2011 ) . Expansion of Vδ2+T-Cells Occurs in Crohn's Disease Patients and Their Siblings: Impact of Therapy and Implications for Pathogenesis . Gastroenterology vol. 140 , ( 5 ) s - 489 .

Duncan J, Sastrillo M, Baker J, Younge L, Anderson S, Lindsay J, Sanderson J, Irving P ( 2011 ) . AN AUDIT OF ADHERENCE TO ANTI-TNF THERAPY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE . GUT . vol. 60 ,

Lindsay JO, Bloom S, Hamlin PJ, Hayward C, Percival F, Bean K, Bodger K ( 2011 ) . AN EVALUATION OF THE IMPACT OF BIOLOGIC THERAPY ON SECONDARY CARE RESOURCE USE ASSOCIATED WITH THE MANAGEMENT OF CROHN'S DISEASE IN THE UK . GUT . vol. 60 ,

Hedin CR, McCarthy NE, Bhattacharjee S, James G, Whelan K, Lindsay JO, Stagg AJ ( 2011 ) . V Delta 2+T CELL EXPANSION IN CROHN'S DISEASE: IMPACT OF INFLAMMATION, DISEASE ACTIVITY AND TREATMENT . GUT . vol. 60 ,

Sebastian S, Jenkins H, Arnott I, Croft N, Ahmad T, McCartney S, Russell RK, Lindsay JO ( 2011 ) . Barriers to transition care in inflammatory bowel disease: a survey of adult and paediatric gastroenterologists in the UK . Gut . vol. 60 ,

Hedin CR, McCarthy NE, Bhattacharjee S, James G, Whelan K, Lindsay JO, Stagg AJ ( 2011 ) . Expansion of Vδ2+T-Cells Occurs in Crohn's Disease Patients and Their Siblings: Impact of Therapy and Implications for Pathogenesis . GASTROENTEROLOGY . vol. 140 , S489 - S489 .

Steel AW, Mela CM, Lindsay JO, Gazzard BG, Goodier MR ( 2011 ) . Increased proportion of CD16(+) NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment . Aliment Pharmacol Ther vol. 33 , ( 1 ) 115 - 126 .

Ng SC, Benjamin JL, McCarthy NE, Hedin CR, Koutsoumpas A, Plamondon S, Price CL, Hart AL et al. ( 2010 ) . Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease . Inflamm Bowel Dis .

McCarthy NE, Hedin CRH, Bhattacharjee S, James GS, Whelan K, Lindsay JO, Stagg AJ ( 2010 ) . Circulating 'gut-tropic' V delta 2 T-cells are expanded in some Crohn's disease patients and their siblings but are ablated by azathioprine therapy . IMMUNOLOGY . vol. 131 , 107 - 107 .

Sanders T, McCarthy N, Gellatly N, Lindsay J, Stagg A ( 2010 ) . Factors from inflamed human intestinal mucosa act on dendritic cells to uncouple the imprinting of gut tropism from FoxP(3)(+) T cell generation . IMMUNOLOGY . vol. 131 , 30 - 31 .

Sanders T, McCarthy N, Gellatly N, Lindsay J, Stagg A ( 2010 ) . Factors from inflamed human intestinal mucosa act on dendritic cells to uncouple the imprinting of gut tropism from FoxP3(+) T cell generation . IMMUNOLOGY . vol. 131 , 134 - 135 .

Hedin CRH, Mullard M, Sharratt E, Jansen C, Sanderson JD, Shirlaw P, Howe LC, Djemal S et al. ( 2010 ) . Probiotic and prebiotic use in patients with inflammatory bowel disease: a case-control study . Inflamm Bowel Dis vol. 16 , ( 12 ) 2099 - 2108 .

Gellatly NL, Sanders TJ, Ahmed M, Mughal S, McCarthy NE, Pattni G, Lindsay JO, Stagg AJ ( 2010 ) . Retinoic acid and aryl hydrocarbon receptor signalling: opposing effects on human dendritic cell differentiation and ability to imprint gut homing . IMMUNOLOGY . vol. 131 , 155 - 155 .

Vossenkämper A, Marchès O, Fairclough PD, Warnes G, Stagg AJ, Lindsay JO, Evans PC, Luong LA et al. ( 2010 ) . Inhibition of NF-κB signaling in human dendritic cells by the enteropathogenic Escherichia coli effector protein NleE . J Immunol vol. 185 , ( 7 ) 4118 - 4127 .

Goodhand J, Dawson R, Hefferon M, Tshuma N, Swanson G, Wahed M, Croft NM, Lindsay JO ( 2010 ) . Inflammatory bowel disease in young people: the case for transitional clinics . Inflamm Bowel Dis vol. 16 , ( 6 ) 947 - 952 .

Russo EA, O'Donnell S, Dearden J, Campbell S, Lindsay JO, O'Morain C, Orchard TR ( 2010 ) . A RETROSPECTIVE SURVEY ON THE LONG-TERM EFFICACY OF THE SECOND BIOLOGIC IN THE MANAGEMENT OF CROHN'S DISEASE: RESULTS FROM A COMBINED ENGLISH IRISH COHORT . GUT . vol. 59 , A64 - A64 .

Benjamin JL, Koutsoumpas A, Hedin CRH, Ng SC, Prescott NJ, Pessoa-Lopes P, Mathew CG, Kamm MA et al. ( 2010 ) . DEMOGRAPHIC, CLINICAL AND GENETIC FACTORS ASSOCIATED WITH DYSBIOSIS IN PATIENTS WITH ACTIVE CROHN'S DISEASE . GUT . vol. 59 , A5 - A5 .

Benjamin JL, Hedin CRH, Koutsoumpas A, Ng SC, Hart AL, Kamm MA, Sanderson JD, Knight SC et al. ( 2010 ) . NO CLINICAL BENEFIT OF PREBIOTICS IN THE TREATMENT OF ACTIVE CROHN'S DISEASE: A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED TRIAL . GUT . vol. 59 , A1 - A2 .

Punekar YS, Sunderland T, Hawkins N, Lindsay J ( 2010 ) . Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease . VALUE HEALTH vol. 13 , ( 2 ) 188 - 195 .

Russo EA, Iacucci M, Lindsay JO, Campbell S, Hart A, Hamlin J, Orchard T, Arebi N et al. ( 2010 ) . Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland . EUR J GASTROEN HEPAT vol. 22 , ( 3 ) 334 - 339 .

Dignass A, Van Assche G, Lindsay JO, Lemann M, Soderholm J, Colombel JF, Danese S, D'Hoore A et al. ( 2010 ) . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management . J CROHNS COLITIS vol. 4 , ( 1 ) 28 - 62 .

Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B et al. ( 2010 ) . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations . J CROHNS COLITIS vol. 4 , ( 1 ) 63 - 101 .

Sharma N, Lindsay J ( 2009 ) . Anti-TNF-Alpha-Induced Psoriasis - An Unusual Paradox . Case Rep Gastroenterol vol. 3 , ( 3 ) 404 - 407 .

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Lindsay JO, Bloom SL ( 2009 ) . Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine mercaptopurine . ALIMENT PHARM THER vol. 30 , ( 6 ) 614 - 620 .

Hedin CRH, Graczer M, Sanderson JD, Lindsay JO, Whelan K ( 2009 ) . Probiotic and prebiotic use by patients with inflammatory bowel disease . Proceedings of The Nutrition Society vol. 68 , ( OCE1 )

Goodhand J, Tang JW, Naik S, Croft N, Lindsay JO ( 2009 ) . W1115 Infliximab Use in Adolescents with Inflammatory Bowel Disease . Gastroenterology vol. 136 , ( 5 ) a - 657 .

Russo EA, Lindsay J, Campbell S, Hart AL, Hamlin PJ, Orchard TR, Arebi N, Nightingale J et al. ( 2009 ) . EXPERIENCE ON THE USE OF ADALIMUMAB AS MAINTENANCE THERAPY IN CROHN'S DISEASE IN ENGLAND AND IRELAND . GUT . vol. 58 , A61 - A62 .

Goodhand J, Tang J, Naik S, Croft NM, Lindsay JO ( 2009 ) . INFLIXIMAB USE IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE . GUT . vol. 58 , A63 - A64 .

Russo EA, Harris AW, Campbell S, Lindsay J, Hart A, Arebi N, Milestone A, Tsai HH et al. ( 2009 ) . Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England . Aliment Pharmacol Ther vol. 29 , ( 3 ) 308 - 314 .

Goodhand J, Swanson G, Hefferon M, Dawson R, Croft NM, Lindsay J ( 2009 ) . P004 - Specialist transitional clinics for adolescents with IBD limit exposure to diagnostic radiation . Journal of Crohn's and Colitis vol. 3 , ( 1 ) s12 - s12 .

Goodhand J, Tang J, Naik S, Croft NM, Lindsay J ( 2009 ) . P207 - Infliximab use in adolescents with IBD . Journal of Crohn's and Colitis vol. 3 , ( 1 ) s92 - s92 .

Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C et al. ( 2008 ) . Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease . ALIMENT PHARM THER vol. 28 , ( 8 ) 973 - 983 .

Lindsay J, Punekar YS, Morris J, Chung-Faye G ( 2008 ) . Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults . Aliment Pharmacol Ther vol. 28 , ( 1 ) 76 - 87 .

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney S, Bloom SL ( 2008 ) . Efficacy of methotrexate in Crohns disease patients previously on thiopurine therapy . GASTROENTEROLOGY vol. 134 , ( 4 ) A661 - A661 .

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney S, Bloom SL, Lindsay JO ( 2008 ) . Efficacy of methotrexate in ulcerative colitis . GASTROENTEROLOGY vol. 134 , ( 4 ) A662 - A662 .

Russo E, Harris A, Campbell S, Lindsay JO, Hart AL, Arebi N, Milestone A, Tsai HH et al. ( 2008 ) . Experience of maintenance infliximab therapy for refractory ulcerative colitis in England . GASTROENTEROLOGY vol. 134 , ( 4 ) A657 - A657 .

Dawson R, Hefferon M, Croft N, Lindsay JO ( 2008 ) . IBD in adolescents: A case control study of disease extent and therapeutic strategy . GASTROENTEROLOGY vol. 134 , ( 4 ) A506 - A506 .

Lindsay JO, Punekar Y, Morris J, Chung-Faye G ( 2008 ) . Is scheduled maintenance treatment with infliximab cost effective in patients with Crohn's disease? . GASTROINTESTINAL ENDOSCOPY . vol. 67 , AB318 - AB318 .

Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al. ( 2008 ) . Production of IL-10 by colonic dendritic cells is associated with higher concentrations of faecal microbiota in patients with active Crohn's disease . GASTROENTEROLOGY . vol. 134 , A653 - A654 .

Dawson R, Hefferon M, Croft N, Lindsay JO ( 2008 ) . T1201 IBD in Adolescents: A Case Control Study of Disease Extent and Therapeutic Strategy . Gastroenterology vol. 134 , ( 4 ) a - 506 .

Koutsoumpas A, Hedin CR, Ng SC, Kamm MA, Sanderson JD, Knight SC, Stagg AJ, Forbes A et al. ( 2008 ) . The concentration and proportion of key bacterial groups of the faecal microbiota are different between smokers and non-smokers with active Crohn's disease . GASTROENTEROLOGY vol. 134 , ( 4 ) A497 - A497 .

Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al. ( 2008 ) . W1201 Production of IL-10 By Colonic Dendritic Cells Is Associated with Higher Concentrations of Faecal Microbiota in Patients with Active Crohn's Disease . Gastroenterology vol. 134 , ( 4 )

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney S, Bloom SL ( 2008 ) . W1235 Efficacy of Methotrexate in Crohns Disease Patients Previously On Thiopurine Therapy . Gastroenterology vol. 134 , ( 4 ) a - 661 .

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney S, Bloom SL, Lindsay JO ( 2008 ) . W1239 Efficacy of Methotrexate in Ulcerative Colitis . Gastroenterology vol. 134 , ( 4 ) a - 662 .

Ng SC, Koutsoumpas A, Hedin CRH, McCarthy N, Plamondon S, Kamm MA, Knight SC, Forbes A et al. ( 2008 ) . P302 PRODUCTION OF IL-10 BY COLONIC DENDRITIC CELLS IS ASSOCIATED WITH HIGHER CONCENTRATIONS OF FAECAL MICROBIOTA IN PATIENTS WITH ACTIVE CROHN'S DISEASE . Journal of Crohn's and Colitis vol. 2 , ( 1 )

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, Lindsay JO, McCartney SA, Bloom SL ( 2008 ) . Efficacy of methotrexate in crohn's disease patients previously on thiopurine therapy . GUT . vol. 57 , A152 - A152 .

Wahed M, Louis-Auguste JR, Baxter LM, Limdi JK, McCartney SA, Bloom SL, Lindsay JO ( 2008 ) . Efficacy of methotrexate in ulcerative colitis . GUT . vol. 57 , A152 - A152 .

Hedin CRH, Koutsoumpas A, Forbes A, Sanderson J, Stagg AJ, Knight SC, Whelan K, Lindsay JO ( 2008 ) . Factors that limit recruitment to clinical trials in crohn's disease . GUT . vol. 57 , A118 - A118 .

Ng SC, Koutsoumpas A, Hedin CR, McCarthy NE, Plamondon S, Kamm MA, Knight SC, Forbes A et al. ( 2008 ) . Production of il-10 by colonic dendritic cells is associated with higher concentrations of faecal microbiota in patients with active crohn's disease . GUT . vol. 57 , A144 - A144 .

Koutsoumpas A, Hedin CRH, Ng SC, Kamm MA, Sanderson JD, Knight SC, Stagg AJ, Forbes A et al. ( 2008 ) . Smokers with active crohn's disease have differences in the concentration and proportion of key bacterial groups of the faecal microbiota . GUT . vol. 57 , A152 - A153 .

Mela CM, Steel A, Lindsay J, Gazzard BG, Gotch FM, Goodier MR ( 2007 ) . Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected individuals . AIDS vol. 21 , ( 16 ) 2177 - 2182 .

Hedin C, Whelan K, Lindsay JO ( 2007 ) . Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials . Proc Nutr Soc . vol. 66 , 307 - 315 .

Wood E, Lindsay JO ( 2007 ) . Trainee colonoscopy audit: North East Thames . GUT . vol. 56 , A104 - A104 .

D’Souza R, Lindsay J ( 2007 ) . Biologic treatments in IBD . Clinical Dilemmas in Inflammatory Bowel Disease ,

Maywood ES, Lindsay JO, Karp J, Powers JB, Williams LM, Titchener L, Ebling FJP, Herbert J et al. ( 2006 ) . Occlusion of the Melatonin‐Free Interval Blocks the Short Day Gonadal Response of the Male Syrian Hamster to Programmed Melatonin Infusions of Necessary Duration and Amplitude . Journal of Neuroendocrinology vol. 3 , ( 3 ) 331 - 337 .

Maywood ES, Grosse J, Lindsay JO, Karp JD, Powers JB, Ebling FJP, Herbert J, Hastings MH ( 2006 ) . The Effect of Signal Frequency on the Gonadal Response of Male Syrian Hamsters to Programmed Melatonin Infusions . Journal of Neuroendocrinology vol. 4 , ( 1 ) 37 - 44 .

Hirri HM, Green PJ, Lindsay J ( 2006 ) . Von Willebrand's disease and angiodysplasia treated with thalidomide . Haemophilia vol. 12 , ( 3 ) 285 - 286 .

Parkes G, Fairclough P, Lindsay JO ( 2006 ) . Endoscopy in high risk cardiovascular patients . GUT . vol. 55 , A56 - A56 .

Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC et al. ( 2006 ) . Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease . Gut vol. 55 , ( 3 ) 348 - 355 .

Lindsay J ( 2006 ) . Medical management of diverticular disease: the role of bulking agents . Diverticular Disease: Emerging Evidence in a Common Condition . Editors: Kruis, W, Forbes, A, Jauch, KW, Kreis, ME et al. , vol. 148 , 155 - 160 .

Al-Hassi HO, Lindsay JO, Whelan K, Gobin P, Forbes A, Kamm MA, Knight SC, Stagg AJ ( 2005 ) . Modulation of intestinal dendritic cells (DC) in Crohn's disease patients taking a fructo-oligosaccharide prebiotic . IMMUNOLOGY vol. 116 , 4 - 4 .

Mawdsley JED, Lindsay J, Rampton D ( 2005 ) . Synbiotic therapy for ulcerative colitis . GUT vol. 54 , ( 9 ) 1346 - 1346 .

Lindsay JO, Whelan K, Stagg A, Gobin P, Omar H, Kamm MA, Knight SC, Forbes A ( 2005 ) . Prebiotic fructo-oligosaccharide as a therapy for Crohn's disease: An open label trial . GUT . vol. 54 , A23 - A24 .

Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJF ( 2004 ) . IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis . Dig Dis Sci vol. 49 , ( 7-8 ) 1327 - 1334 .

Lindsay JO ( 2004 ) . Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis (Retraction of vol 52, pg 981, 2003) . GUT vol. 53 , ( 5 ) 774 - 774 .

Lindsay JO, Andreyev HJN, Vlavianos P, Westaby D ( 2004 ) . Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass . Aliment Pharmacol Ther vol. 19 , ( 8 ) 901 - 905 .

Ansari A, Arenas M, Lindsay J, Morris D, Greenfield S, Raoof S, Fong F, Fairbanks L et al. ( 2004 ) . Pharmacogenetic profiling in azathioprine treatment: TPMT, ITPA, and MTHFR polymorphisms and toxicity . GUT . vol. 53 , A105 - A105 .

Ansari A, Arenas M, Lindsay J, Morris D, Greenfield S, Soon SL, Fairbanks S, Duley J et al. ( 2004 ) . Prospective study of thioguanine nucleotide measurement during azathioprine treatment for inflammatory bowel disease . GUT . vol. 53 , A105 - A105 .

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ ( 2003 ) . Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis . Gut vol. 52 , ( 7 ) 981 - 987 .

Lindsay JO, Vlavianos P, Andreyev HJN, Westaby D ( 2003 ) . Enteral stents for the palliation of malignant gastric and duodenal obstruction . GUT . vol. 52 , A72 - A72 .

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ ( 2003 ) . Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis . Gut vol. 52 , ( 3 ) 363 - 369 .

Lindsay J, Van Montfrans C, Brennan F, Van Deventer S, Drillenburg P, Hodgson H, Te Velde A, Sol Rodriguez Pena M ( 2002 ) . IL-10 gene therapy prevents TNBS-induced colitis . Gene Ther vol. 9 , ( 24 ) 1715 - 1721 .

Lindsay JO, van Montfrans C, te Velde AA, Brennan FM, Hodgson HJF, Pena MSR ( 2002 ) . IL-10 gene therapy ameliorates TNBS induced colitis . GUT vol. 50 , A14 - A14 .

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan F, Hodgson HJF ( 2002 ) . Local IL-10 gene therapy induces colonic IL-10 release and is therapeutic for murine colitis . GUT vol. 50 , A30 - A30 .

Lindsay JO ( 2002 ) . Interleukin-10 gene therapy: A cure for Crohn's disease? . CME Journal Gastroenterology, Hepatology and Nutrition vol. 5 , ( 1 ) 11 - 14 .

Lindsay JO, Hodgson HJ ( 2001 ) . Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease? . Aliment Pharmacol Ther vol. 15 , ( 11 ) 1709 - 1716 .

Lindsay JO, Ciesielski CJ, Scheinin T, Hodgson HJ, Brennan FM ( 2001 ) . The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10 . J Immunol vol. 166 , ( 12 ) 7625 - 7633 .

LINDSAY JO, Brennan FM, Hodgson HJF, Scheinin T, Ciesielski CJ ( 2001 ) . The prevention and treatment of murine colitis using adenoviral vectors encoding interleukin-10 . Journal of Immunology vol. 166 , 7625 - 7633 .

Lindsay JO, Ciesielski CJ, Brennan FM, Hodgson HJ ( 2001 ) . Rectal administration of an adenoviral vector encoding IL-10 induces colonic IL-10 release with minimal anti-adenoviral response . GASTROENTEROLOGY vol. 120 , ( 5 ) A687 - A688 .

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ ( 2001 ) . The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding interleukin-10 . GASTROENTEROLOGY vol. 120 , ( 5 ) A686 - A686 .

Lindsay JO, Ciesielski CJ, Scheinin T, Brennan F, Hodgson HJF ( 2001 ) . The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding interleukin-10 . GUT vol. 48 , A109 - A109 .

Lindsay JO, Taylor Robinson SD, Jackson JE, Walters JRF ( 2000 ) . Erratum: The investigation of iron deficiency anemia - A hospital based audit (Hepato-Gastroenterology (1999) 46 (2887-2890)) . Hepato-Gastroenterology vol. 47 , ( 31 )

Lindsay JO, Robinson SD, Jackson JE, Walters JR ( 1999 ) . The investigation of iron deficiency anemia--a hospital based audit . Hepatogastroenterology vol. 46 , ( 29 ) 2887 - 2890 .

Mumford AD, Vulliamy T, Lindsay J, Watson A ( 1998 ) . Hereditary hyperferritinemia-cataract syndrome: two novel mutations in the L-ferritin iron-responsive element . Blood vol. 91 , ( 1 ) 367 - 368 .

Arnold JD, Mumford AD, Lindsay JO, Hegde U, Hagan M, Hawkins JR ( 1997 ) . Hyperferritinaemia in the absence of iron overload . Gut vol. 41 , ( 3 )

Kozaki K, Egawa H, Garcia‐Kennedy R, Cox KL, Lindsay J, Esquivel CO ( 1995 ) . Hepatic failure due to massive iron ingestion successfully treated with liver transplantation . Clinical Transplantation vol. 9 , ( 2 ) 85 - 87 .